Monobody compositions and methods of use

A monobody and degrader fusion protein targeting NR4A3 addresses T cell exhaustion in engineered T cell therapies, improving the efficacy of cancer immunotherapy by preventing NR4A3-mediated dysfunction.

WO2026236690A1PCT designated stage Publication Date: 2026-11-12OUTPACE BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027410
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing engineered T cell therapies, such as CAR-T and TCR-T cell therapies, face challenges due to T cell exhaustion, which is mediated by NR4A transcription factors, leading to reduced efficacy in cancer immunotherapy.

Method used

Development of a monobody that specifically binds to NR4A3 and a degrader capable of degrading NR4A3, fused to form a fusion protein that can be expressed in cells to prevent NR4A3-mediated exhaustion, thereby enhancing the functionality of engineered T cells.

Benefits of technology

The fusion protein effectively prevents T cell exhaustion, improving the persistence and functionality of engineered T cells, thereby enhancing the therapeutic efficacy of cancer immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027410_12112026_PF_FP_ABST
    Figure US2026027410_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure is related to polypeptides comprising a monobody that bind Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3). The present disclosure further relates to a degrader capable of degrading a target heterologous protein (e.g., a protein of a nuclear receptor subfamily 4 group A (NR4A) family). The disclosure comprises a fusion of the two proteins, and uses thereof, such as to selectively degrading NR4A3 protein, to increase the efficiency of immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

MONOBODY COMPOSITIONS AND METHODS OF USE CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 803,271, filed May 9, 2025, which is hereby incorporated by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0002] The content of the electronically submitted Sequence Listing XML (File Name 5684_001PC01_SequenceListing_ST26.xml; Size: 132,612 bytes; and Date of Creation: May 7, 2026) filed with the application is incorporated herein by reference in its entirety.FIELD OF THE DISCLOSURE

[0003] The present disclosure is related to polypeptides comprising a monobody that bind Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3). The present disclosure further relates to a degrader capable of degrading a target heterologous protein (e.g., a protein of a nuclear receptor subfamily 4 group A (NR4A) family). The disclosure comprises a fusion of the two proteins, and uses thereof, such as to selectively degrading NR4A3 protein, to increase the efficiency of immunotherapy.INTRODUCTION

[0004] Cancer immunotherapy relies on getting T cells — the immune system’s primary killers of infected and diseased cells — to attack and kill tumor cells. Immune checkpoint blockade, chimeric antigen receptor (CAR) T cell therapy, and T cell receptor-engineered (TCR) T cell therapy are treatments that make use of functionally active T cells isolated from patients and require highly functional T cells in order to be effective.

[0005] However, T cells undergo a physiological change called exhaustion, characterized by progressive loss of function and changes in transcriptional profiles. T cell exhaustion is mediated by a cascade of signaling molecules culminating in transcription factors that regulate the expression of genes that modulate T cell exhaustion. Exhausted T cells lose their high proliferative capacity and cytotoxicity, eventually leading to cell death. Numerous factors can lead to T cellexhaustion, such as persistent antigen exposure during infection, and constant alloantigen presence following organ transplantation. In addition, some tumors and cancer-associated cells can actively induce T cell exhaustion at the site of the tumor, thus conferring tumor protection from T cell activity. T cell exhaustion is also seen in the context of engineered T cell therapies. Engineered T cells expressing a chimeric antigen receptor (CAR) or T cell receptor (TCR) can undergo exhaustion in the same way that endogenous T cells undergo exhaustion.

[0006] It has been shown that CAR-T cells lacking all three NR4A transcription factors (triple knockout NR4A 1, NR4A2, NR4A3) promoted tumor regression and prolonged the survival of tumor-bearing mice (Chen et al. Nature 567: 530-534 (2019); Nakagawa et al., J Immunother Cancer. 2024 Aug 16;12(8):e008665.) However, knocking out all three NR4A genes imposes significant technically challenges. As such, there remains a need in the art for delaying or reducing T cell exhaustion for improved engineered T cell therapies.BRIEF SUMMARY OF THE DISCLOSURE

[0007] In some aspects, provided herein is a monobody or antigen-binding portion thereof specifically binding to nuclear receptor subfamily 4 group A member 3 (NR4A3) (“NR4A3 monobody) comprising an FG loop, a DE loop, and a BC loop, wherein the FG loop comprises the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 103. In some aspects, the BC loop comprises the amino acid sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 101. In some aspects, the DE loop comprises the amino acid sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 102. In some aspects, the FG loop, DE loop, and BC loop comprise (i) the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 3, respectively, (ii) the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 4, respectively, or (ii) the amino acid sequence as set forth in SEQ ID NO: 103, SEQ ID NO: 102, and SEQ ID NO: 101, respectively. In some aspects, the NR4A3 monobody does not bind to NR4A1 or NR4A2. In some aspects, the NR4A3 protein comprises the amino acid sequence as set forth in SEQ ID NO: 91. In some aspects, the NR4A3 monobody binds to a ligand binding domain (LBD) of the NR4A3. In some aspects, the LBD of the NR4A3 comprises amino acids amino acids 394-626 of SEQ ID NO: 91. In some aspects, provided herein is a NR4A3 monobody comprising the amino acid sequence as set forth in SEQ ID NO: 21. In some aspects, provided herein is a NR4A3 monobody comprising the amino acid sequence as set forth in SEQ ID NO: 22. In some aspects, provided herein is aNR4A3 monobodycomprising the amino acid sequence as set forth in SEQ ID NO: 23. In some aspects, provided herein is a fusion protein comprising the NR4A3 monobody disclosed herein and a degrader, which is capable of degrading NR4A3. In some aspects, provided herein is a degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in any one of SEQ ID NO: 45-51. In some aspects, provided herein is a fusion protein comprising the degrader disclosed herein, and a binding moiety that specifically binds to the heterologous protein.

[0008] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NO: 70 to SEQ ID NO: 85. In some aspects, the fusion protein further comprises a moiety that binds to a tumor associated antigen.

[0009] In some aspects, provided herein is a cell or cells that are modified or engineered with the NR4A3 monobody disclosed herein, the degrader disclosed herein, or the fusion protein disclosed herein, or the composition disclosed herein. In some aspects, the cell or cells comprises a T cell, a B cell, an NK cell, a tumor infiltrating lymphocyte, or any combination thereof. The cell or cells may comprise in vivo cells, in vitro cells, or ex vivo cells.

[0010] In some aspects, provided herein is a method of preventing exhaustion in a cell, the method comprising introducing the NR4A3 monobody disclosed herein, the degrader disclosed herein, or the fusion protein disclosed herein, the composition disclosed herein, the polynucleotide disclosed herein the vector disclosed herein, into a cell under conditions sufficient for expression of the monobody, degrader, the fusion protein, the composition, the polynucleotide or, or the vector.

[0011] In some aspects, provided herein is a method of method of treating a disease or a condition in a subject in need thereof comprising administering to the subject the NR4A3 monobody disclosed herein, the degrader disclosed herein, or the fusion protein disclosed herein, the composition disclosed herein, the polynucleotide disclosed herein the vector disclosed herein, or the cell disclosed herein.BRIEF DESCRIPTION OF THE DRAWINGS / FIGURES

[0012] FIG. 1 illustrates design elements of the disclosure where the target is a ligand binding domain of the NR4A receptor. Shown generally in this diagram is an engineered protein regulator of the present disclosure comprising both degrader and binder (monobody) domains that have been optimized to bind to and degrade the target (NR4A3).

[0013] FIG. 2 represents the flow cytometry degradation screen used to identify degrader domains capable of down-regulating the NR4A3 target protein. DHD is an abbreviation for designed heterodimer.

[0014] FIG. 3 shows an exemplary monobody of the present disclosure (SEQ ID NO: 21) that binds to (a) NR4A3 with high affinity (Kd ~ 9 nM) and (b) has no binding affinity with respect to NR4A1 using Octet® BLI binding quantitation assay.

[0015] FIG. 4 shows the exemplary monobodies of the present disclosure (SEQ ID NOS: 23 and 21) bind to NR4A3 but do not bind to NR4A1 and NR4A2 in solution using Octet® BLI binding quantitation assay.

[0016] FIG. 5 shows the exemplary monobodies of the present disclosure (SEQ ID NOS: 23 and 21) bind strongly to NR4A3 even after a freeze / thaw temperature cycle.

[0017] FIG. 6 shows three exemplary engineered protein regulators that are capable of degrading overexpressed NR4A3 target in primary human T cells but that do not degrade overexpressed NR4A2 or NR4A1.

[0018] FIG. 7A is a representation of the exemplary tumor killing assay of the disclosure. Briefly, T-cells of the disclosure expressing a chimeric antigen receptor (CAR) are introduced into tumor cells to generate an in vitro coculture. After four passages of the co-culture, tumor killing and cytokine production are measured as shown in the following figures.

[0019] FIG. 7B show the enhanced CAR-T cell function when in the tumor cell killing assay depicted in FIG 7A, exemplary engineered protein regulators are co-expressed with the CAR compared to CAR plus NR4A3 gene knock-out (KO) or CAR only by measuring tumor killing (AUC) and IFN-y production (pg / mL) using two separate donor cells; higher IFN-y production and lower AUC indicate more potent CAR T cell function.

[0020] FIG. 7C demonstrate that in the tumor cell killing assay depicted in FIG 7A, T cells expressing the engineered protein regulators of the present disclosure with the binder (monobody) at either the N-terminus or C-terminus of the SPOP(167-374) ligase (degrader) domain enhance CAR T cell function. “CAR only” comprises an anti-RORl CAR (comprising SEQ ID NO: 99)without an engineered protein regulator of the disclosure, and “Mock” is a negative control generated by performing the transduction with an empty vector.DETAILED DESCRIPTION OF THE DISCLOSURE

[0021] The present disclosure comprises a novel monobody or antigen-binding portion thereof specifically binding to nuclear receptor subfamily 4 group A member 3 (NR4A3) (“NR4A3 monobody) and / or a novel degrader that is capable of degrading a heterologous protein. When a monobody disclosed herein is fused to a degrader, e.g., a degrader disclosed herein, and expressed in a cell, the monobody can bind to endogenous NR4A3 and thus can allow the endogenous NR4A3 to be degraded, thereby conditioning the cell for a chimeric antigen receptor or T cell receptor cell therapy.

[0022] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to the particular compositions or process steps described, as such can, of course, vary. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which can be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0023] The headings provided herein are not limitations of the various aspects of the disclosure, which can be defined by reference to the specification as a whole. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.I. DEFINITIONS

[0024] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application.

[0025] Throughout this disclosure, the term “a” or “an” entity refers to one or more of that entity; for example, “an immune cell,” is understood to represent one or more immune cells. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.

[0026] Furthermore, “and / or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0027] It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of’ and / or “consisting essentially of’ are also provided.

[0028] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.

[0029] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0030] Abbreviations used herein are defined throughout the present disclosure. Various aspects of the disclosure are described in further detail in the following subsections.

[0031] The terms “about” or “comprising essentially of’ refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, z.e., the limitations of the measurement system. For example, “about” or “comprising essentially of’ can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, “about” or “comprising essentially of’ can mean a range of up to 10%. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” or“comprising essentially of’ should be assumed to be within an acceptable error range for that particular value or composition.

[0032] As used herein, the term “approximately,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In some aspects, the term “approximately” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0033] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.

[0034] As used herein, “administering” refers to the physical introduction of a therapeutic agent or a composition comprising a therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. The different routes of administration for a therapeutic agent described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, intratracheal, pulmonary, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraventricle, intravitreal, epidural, and intrastemal injection and infusion, as well as in vivo electroporation. Alternatively, a therapeutic agent described herein can be administered via a non-parenteral route, such as a topical, epidermal, or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually, or topically. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0035] As used herein, the term “antigen” refers to any natural or synthetic immunogenic substance, such as a protein, peptide, or hapten. As used herein, the term “cognate antigen” refers to an antigen which an immune cell (e.g., T cell) recognizes and thereby, induces the activation of the immune cell (e.g., triggering intracellular signals that induce effector functions, such as cytokine production, and / or for proliferation of the cell).

[0036] Nucleotides are referred to by their commonly accepted single-letter codes. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation. Nucleotides are referred to herein by their commonly known one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Accordingly, A represents adenine, C represents cytosine, G represents guanine, T represents thymine, U represents uracil.

[0037] It is to be understood that in the disclosed sequences T and U are interchangeable depending on whether the sequence is a DNA or an RNA.

[0038] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation.

[0039] A “polypeptide” refers to a chain comprising at least two consecutively linked amino acid residues, with no upper limit on the length of the chain. One or more amino acid residues in the protein can contain a modification such as, but not limited to, glycosylation, phosphorylation or disulfide bond formation. A “protein” can comprise one or more polypeptides. Unless otherwise specified, the terms “protein” and “polypeptide” can be used interchangeably.

[0040] The term “monobody” as used herein refers to fibronectin based scaffolds, e.g, Fn3 domain, any functional fragments, and / or any functional variants, in which one or more of the solvent accessible loops has been randomized or mutated. In some aspects, the Fn3 domain is an Fn3 domain derived from the wild-type tenth module of the human fibronectin type III domain (10Fn3):VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVOEFTV PGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (SEQ ID NO: 20).In the monobody sequence, the BC, DE and FG loops that may be mutated are underlined. As used herein, the term “mononody” can be interchangeably used with “10Fn3”.

[0041] As described herein, non-ligand binding sequences of10Fn3 or monobody may be altered provided that the monobody retains ligand binding function and / or structural stability. A variety of mutant monobodies have been reported. In some aspects, one or more of Asp 7, Glu 9, and Asp 23 is replaced by another amino acid, such as, for example, a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.). These mutations have been reported to have the effect of promoting greater stability of the monobody at neutral pH as compared to the wild-type form (See, PCT Publication No. WO 02 / 04523). A variety of additional alterations in the monobody that areeither beneficial or neutral have been disclosed. See, for example, Batori et al, Protein Eng., 15(12): 1015-1020 (Dec. 2002); Koide et al, Biochemistry, 40(34): 10326-10333 (Aug. 28, 2001).

[0042] Both variant and wild-type monobody sequences are characterized by the same structure, namely seven beta-strand domain sequences designated A through G and six loop regions (AB loop, BC loop, CD loop, DE loop, EF loop, and FG loop) which connect the seven beta-strand domain sequences. The beta strands or sheets positioned closest to the N- and C-termini may adopt a beta-like conformation in solution. In SEQ ID NO: 20, the AB loop corresponds to residues 15-16, the BC loop corresponds to residues 21-30, the CD loop corresponds to residues 39-45, the DE loop corresponds to residues 51-55, the EF loop corresponds to residues 60-66, and the FG loop corresponds to residues 76- 87 (Xu et al, Chemistry & Biology, 9:933-942 (2002)).

[0043] The terms “antigen binding portion”, “portion of a monobody”, or “a monobody fragment” refers to any portion of a monobody less than the whole that can specifically bind to the same antigen, e.g., NR4A3, as the full monobody with a KD of less than 1 X 106M. An antigen binding portion can include the loops that bind to the DNA binding domain of NR4A3.

[0044] The term “degrader” as used herein refers to any protein, fragment, and / or variant that is capable of degrading a heterologous protein, e.g., NR4A3. In some aspects, the degrading can occur by recruiting cell’s protein degradation machinery, for example the ubiquitin-proteasome system (UPS). Degraders can label the target protein with ubiquitin molecules, and the labeled proteins can be recognized and broken down by the proteasome. In some aspects, a degrader comprises a ligase, e.g., ubiquitin ligase. A ubiquitin ligase (also called an E3 ubiquitin ligase) is a protein that recruits an E2 ubiquitin-conjugating enzyme that has been loaded with ubiquitin, recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin from the E2 to the protein substrate. The ubiquitin, once it reaches its destination, ends up being attached by an isopeptide bond to a lysine residue, which is part of the target protein. E3 ligases interact with both the target protein and the E2 enzyme, and so impart substrate specificity to the E2. Commonly, E3s polyubiquitinate their substrate with Lys48-linked chains of ubiquitin, targeting the substrate for destruction by the proteasome. Many other types of linkages are possible and alter a protein’s activity, interactions, or localization. Ubiquitination by E3 ligases regulates diverse areas such as cell trafficking, DNA repair, and signaling. Therefore, the term “functional domain” of a degrader means a domain (or a fragment) of E3 ligases that is capable of ubiquitinating its substrate by allowing El and E2 enzymes to interact with E3 to transfer the ubiquitin to the substrate.

[0045] As used herein, a “fragment” of a polypeptide, or a “truncated polypeptide” may refer to an amino acid sequence of a polypeptides that is shorter than a reference sequence. In some aspects, the reference sequence comprises or consists of a naturally-occurring sequence. In comparison to a reference sequence, the fragment may comprise an N-terminal or a C-terminal deletion (optionally referred to as a truncation). Alternatively, or in addition, in comparison to a reference sequence, the fragment may comprise an internal deletion at any one or more amino acid positions of the polypeptides. Polypeptides of the disclosure may be provided as a fragment or a truncated version of a reference polypeptides. Moreover, all possible fragments and truncated variants of the polypeptides of the disclosure are contemplated in the aspects or embodiments provided in this disclosure.

[0046] As used herein, the term “functional fragment” refers to a polypeptides fragment that retains a function of the polypeptides. Accordingly, in some aspects, a functional fragment of a bioactive peptide, such as an enzyme, retains the ability to catalyze a biological action, because the functional fragment comprises a catalytic domain of the enzyme. Polypeptides of the disclosure may be provided as a fragment or a truncated version of a reference polypeptides. Moreover, all possible fragments and truncated variants of the polypeptides of the disclosure are contemplated in the aspects or embodiments provided in this disclosure. In some aspects, a functional fragment of the disclosure retains a function of the polypeptides even if the activity of the functional fragment or the efficacy of the functional fragment is modified when compared to the full-length polypeptides. In some aspects, a functional fragment of the disclosure retains a function of the polypeptides even if the activity of the functional fragment or the efficacy of the functional fragment is decreased when compared to the full-length polypeptides.

[0047] As used herein, the term “functional variant” of a protein refers to a modified form of a polypeptide, fragment, or a member of a class of polypeptides, which maintains the function of the polypeptides. In some aspects, a functional variant of the disclosure retains a function of the polypeptides even if the activity of the functional variant or the efficacy of the functional variant is modified when compared to the unmodified polypeptides. In some aspects, a functional variant of the disclosure retains a function of the polypeptides even if the activity of the functional variant or the efficacy of the functional variant is decreased when compared to the unmodified polypeptides.

[0048] The term “nucleic acid molecule,” as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule can be single- stranded or doublestranded, and can be cDNA.

[0049] The term “polynucleotide” as used herein refer to polymers of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. This term refers to the primary structure of the molecule. Thus, the term includes triple-, double- and single-stranded deoxyribonucleic acid (“DNA”), as well as triple-, double- and single-stranded ribonucleic acid (“RNA”). It also includes modified, for example by alkylation, and / or by capping, and unmodified forms of the polynucleotide. More particularly, the term “polynucleotide” includes polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), including mRNAs and gRNAs, whether spliced or unspliced, any other type of polynucleotide which is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing normucleotidic backbones, for example, polyamide (e.g., peptide nucleic acids “PNAs”) and polymorpholino polymers, and other synthetic sequence-specific nucleic acid polymers providing that the polymers contain nucleobases in a configuration which allows for base pairing and base stacking, such as is found in DNA and RNA. Unless indicated otherwise, the term “polynucleotides,” “nucleic acids,” “gene,” “cDNA,” and “mRNA” can be used interchangeably.

[0050] The term “gene” means the segment of DNA involved in producing a polypeptide chain. It can include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

[0051] The term “vector,” as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, also included are other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0052] A “cancer” refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream. “Cancer” as used herein refers to primary, metastatic and recurrent cancers.

[0053] As used herein, the term “immune response” refers to a biological response within a vertebrate against foreign agents, which response protects the organism against these agents and diseases caused by them. An immune response is mediated by the action of a cell of the immune system e.g., a T lymphocyte, B lymphocyte, natural killer (NK) cell, macrophage, eosinophil, mast cell, dendritic cell or neutrophil) and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and / or elimination from the vertebrate’s body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues. An immune reaction includes, e.g., activation or inhibition of a T cell, e.g., an effector T cell or a Th cell, such as a CD4+or CD8+T cell, or the inhibition of a Tregcell. As used herein, the term “T cell” and “T lymphocytes” are interchangeable and refer to any lymphocytes produced or processed by the thymus gland. In some aspects, a T cell is a CD4+T cell. In some aspects, a T cell is a CD8+T cell. In some aspects, a T cell is a NKT cell.

[0054] A “subject” includes any human or nonhuman animal. The term “nonhuman animal” includes, but is not limited to, vertebrates such as nonhuman primates, sheep, dogs, and rodents such as mice, rats and guinea pigs. In some aspects, the subject is a human. The terms “subject” and “patient” are used interchangeably herein.

[0055] The term “therapeutically effective amount” or “therapeutically effective dosage” refers to an amount of an agent (e.g., a modified immune cells disclosed herein) that provides the desired biological, therapeutic, and / or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In reference to solid tumors, an effective amount comprises an amount sufficient to cause a tumor to shrink and / or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation. In some aspects, an effective amount is an amount sufficient to delay tumor development. In some aspects, an effective amount is an amount sufficient to prevent or delay tumor recurrence. An effective amount can be administered in one or moreadministrations. The effective amount of the composition can, for example, (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and can stop cancer cell infiltration into peripheral organs; (iv) inhibit ( / .< ., slow to some extent and can stop tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer.

[0056] In some aspects, a “therapeutically effective amount” is the amount of the modified cell herein clinically proven to affect a significant decrease in cancer or slowing of progression (regression) of cancer, such as an advanced solid tumor. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.

[0057] The terms “effective” and “effectiveness” with regard to a treatment includes both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of the drug to promote cancer regression in the patient. Physiological safety refers to the level of toxicity, or other adverse physiological effects at the cellular, organ and / or organism level (adverse effects) resulting from administration of the drug.

[0058] As used herein, the term “immune checkpoint inhibitor” refers to molecules that totally or partially reduce, inhibit, interfere with or modulate one or more checkpoint proteins. Checkpoint proteins regulate T-cell activation or function. Numerous checkpoint proteins are known, such as CTLA-4 and its ligands CD80 and CD86; and PD-1 with its ligands PD-L1 and PD-L2. Pardoll, D.M., Nat Rev Cancer 12(4):252-64 (2012). These proteins are responsible for costimulatory or inhibitory interactions of T-cell responses. Immune checkpoint proteins regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses. Immune checkpoint inhibitors include antibodies or are derived from antibodies.

[0059] The terms “chimeric antigen receptor” and “CAR,” as used herein, refer to a recombinant fusion protein that has an antigen-specific extracellular domain coupled to an intracellular domain that directs the cell to perform a specialized function upon binding of an antigen to the extracellular domain. The terms “artificial T cell receptor,” “chimeric T-cell receptor,” and “chimeric immunoreceptor’ ’ can each be used interchangeably herein with the term “chimeric antigen receptor.” Chimeric antigen receptors are distinguished from other antigen binding agents by their ability to both bind MHC-independent antigen and transduce activation signals via their intracellular domain.

[0060] The terms “T cell receptor” and “TCR”, as used herein, refer to a protein complex found on the surface on T cells, responsible for recognizing specific antigens. It is a key player in T cell activation, which is essential for the immune system to mount an effective response to pathogens and other threats. TCR as used herein can be an engineered protein that comprises an antigen binding portion of TCR. The TCR when engineered to be expressed on cells can target an antigen, e.g., tumor associated antigen.

[0061] The antigen-specific domain of a CAR or TCR recognizes and specifically binds an antigen, typically a surface-expressed antigen of a malignancy. An antigen-specific domain specifically binds an antigen when, for example, it binds the antigen with an affinity constant or affinity of interaction (KD) between about 0.1 pM to about 10 pM, for example, about 0.1 pM to about 1 pM or about 0.1 pM to about 100 nM. Methods for determining the affinity of interaction are known in the art. An antigen-specific domain suitable for use in a TCR or CAR of the present disclosure can be any antigen-binding polypeptide, a wide variety of which are known in the art. In some aspects, the antigen-binding domain is a single chain Fv (scFv). Other antibody-based recognition domains (cAb VHH (camelid antibody variable domains) and humanized versions thereof, IgNAR VH (shark antibody variable domains) and humanized versions thereof, sdAb VH (single domain antibody variable domains) and “camelized” antibody variable domains are suitable for use. In some aspects, T cell receptor (TCR) based recognition domains, such as single chain TCR (scTv, single chain two-domain TCR containing V.alpha.V.beta.) are also suitable for use.

[0062] A CAR disclosed herein can also include an intracellular domain that provides an intracellular signal to the cell (expressing the CAR) upon antigen binding to the antigen-specific extracellular domain. In some aspects, the intracellular signaling domain of a CAR is responsible for activation of at least one of the effector functions of the T cell in which the chimeric receptor is expressed.

[0063] The term “intracellular domain” refers to the portion of a CAR that transduces the effector function signal upon binding of an antigen to the extracellular domain and directs the T cell to perform a specialized function. Non-limiting examples of suitable intracellular domains include the zeta chain of the T-cell receptor or any of its homologs (e.g., eta, delta, gamma, or epsilon), MB 1 chain, 829, Fc RIII, Fc RI, and combinations of signaling molecules, such as CD3.zeta., and CD28, CD27, 4-1BB, DAP-10, 0X40, and combinations thereof, as well as other similar molecules and fragments. Intracellular signaling portions of other members of the families of activating proteins can be used, such as FcyRIII and FcsRI. While usually the entire intracellular domain will be employed, in many cases it will not be necessary to use the entire intracellularpolypeptide. To the extent that a truncated portion of the intracellular signaling domain can find use, such truncated portion can be used in place of the intact chain as long as it still transduces the effector function signal. The term intracellular domain is thus meant to include any truncated portion of the intracellular domain sufficient to transduce the effector function signal. Typically, the antigen-specific extracellular domain is linked to the intracellular domain of the chimeric antigen receptor by a transmembrane domain. A transmembrane domain traverses the cell membrane, anchors the CAR to the T cell surface, and connects the extracellular domain to the intracellular signaling domain, thus impacting expression of the CAR on the T cell surface. Chimeric antigen receptors can also further comprise one or more costimulatory domain and / or one or more spacer. A costimulatory domain is derived from the intracellular signaling domains of costimulatory proteins that enhance cytokine production, proliferation, cytotoxicity, and / or persistence in vivo.

[0064] A “peptide hinge” or “spacer” connects the antigen-specific extracellular domain to the transmembrane domain. The transmembrane domain is fused to the costimulatory domain, optionally a costimulatory domain is fused to a second costimulatory domain, and the costimulatory domain is fused to a signaling domain, not limited to CD3(^. For example, inclusion of a spacer domain between the antigen-specific extracellular domain and the transmembrane domain, and between multiple scFvs in the case of tandem CAR, can affect flexibility of the antigen-binding domain(s) and thereby CAR function. Suitable transmembrane domains, costimulatory domains, and spacers are known in the art.

[0065] As used herein, the terms “ug” and “uM” are used interchangeably with “pg” and “pM,” respectively.

[0066] “Coding sequence” or “encoding nucleic acid” as used herein means the nucleic acids (RNA or DNA molecule) that comprise a nucleotide sequence which encodes a protein, e.g., a Cas9 protein, a CAR, or a TCR, or a polynucleotide, e.g., a gRNA. The coding sequence can further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence can be codon optimized.

[0067] Various aspects described herein are described in further detail in the following subsections.II. EXEMPLARY POLYPEPTIDES AND COMPOSITIONS

[0068] The present disclosure comprises two types of proteins. One is a monobody (or an antigen binding portion of the monobody) that binds to NR4A3, and another is a degrader that is capable of degrading a target heterologous protein (e.g., a protein of a nuclear receptor subfamily 4 group A (NR4A) family). . The disclosure also comprises a fusion of the two proteins, which is also referred to as an “engineered protein regulator”. In some aspects, the novel monobody disclosed herein can be fused to any moiety that is capable of degrading the target that the monobody binds to, e.g., a protein, e.g., a degrader. In some other aspects, the novel degrader disclosed herein can be fused to any moiety that binds to a protein of the NR4A family.ILA. NR4A3 Monobody

[0069] The monobody described in this disclosure can be used to reprogram cell signaling pathways, allowing cells to autonomously respond to changes in cell state or signaling within the tumor microenvironment, leading to a more durable therapeutic response. Specifically, the compositions disclosed here regulate the DNA-binding activities of intracellular proteins, including transcription factors, in response to antigen stimulation, thereby overcoming dysfunction. CAR-T cells or TCR-T cells often experience exhaustion due to chronic stimulation, which is a form of dysfunction addressed by these compositions. By modulating the binding of pro-exhaustion transcription factors to DNA, these compositions can prevent cell exhaustion and promote long-term persistence, adjusting to evolving cellular conditions. In some aspects, the present disclosure provides a monobody or antigen-binding portion thereof specifically binding to Nuclear Receptor Subfamily 4 Group A Member 3 (“NR4A3 monobody”).

[0070] Nuclear Receptor Subfamily 4 Group A Member 3 (or NR4A3), also known as MINOR, CSMF, NORI, CHN, Mitogen-Induced Nuclear Orphan Receptor, Neuron-Derived Orphan Receptor 1, Nuclear Hormone Receptor NOR- 1, “Chondrosarcoma, Extraskeletal Myxoid, Fused to EWS,” and Translocated In Extraskeletal Chondrosarcoma (TEC)), is a protein which in humans is encoded by the NR4A3 gene. NR4A3 is a transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. NR4A3 induces gene expression by binding as monomers to the NGFI-B Response Element (NBRE) 5’-AAAAGGTCA-3’ site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (by similarity) and plays a role in the regulation of proliferation, survival, and differentiation of many different cell types. As such, by modulating theability of NR4A3 to bind DNA, compositions of the disclosure can inhibit cell exhaustion and promote persistence in a nuanced manner, responsive to changing cellular conditions.

[0071] The NR4A family also includes NR4A1 (also known as HMR, N10, TR3, NP10, GFRP1, NAK-1, NGFIB, and NUR77) and NR4A2 (also known as NOT, RNR1, HZF-3, NURR1, TINUR). Sequence information of the NR4A3 proteins are provided in Table 3 (e.g., the amino acid sequences of SEQ ID NOs: 91-98).

[0072] The NR4A3 monobody of the disclosure can be used to specifically bind NR4A that facilitate certain physiological processes. One such process can be T cell exhaustion. Thus, the polypeptides of the disclosure can be used to specifically bind transcription factors such as NR4A and its isoforms in order to reduce T cell exhaustion.

[0073] In some aspects, the NR4A3 monobody disclosed herein is derived from a human fibronectin type III domain (Fn3) domain. Non-limiting examples of such Fn3 domain include the wild-type tenth module of the human fibronectin type III domain (10Fn3) or functional variants thereof, el0-FN3 (Olson et al., Protein Sci. 2007;16:476-484), FN3con (Porebski et al., Protein Eng. Des. Sei. 2015; 28: 67-78), and the third fibronectin type III domain of tenascin C (Tn3) or functional variants thereof (Gilbreth et al., Protein Eng. Des. Sei. 2014; 27:411-418). Both variant and wild-type Fn3 domains may be characterized by the same structure, namely seven beta strand (or referred as sheet elsewhere herein) sequences and six loop regions which connect the seven sheet sequences. In some aspects, the loop regions may comprise an altered amino acid sequence relative to the sequence of the corresponding loop of the wild-type human Fn3 domain. The term “altered” as used herein refers to one or more amino acid sequence alterations relative to a corresponding human fibronectin type III domain and includes amino acid additions, deletions, and substitutions. Altering an amino acid sequence may be accomplished through intentional, blind, or spontaneous sequence variation, generally of a nucleic acid coding sequence, and may occur by any technique, for example, PCR, error-prone PCR, or chemical DNA synthesis.

[0074] In some aspects, the monobody disclosed herein may comprise at least seven sheet sequences designated N-terminus to C-terminus A, B, C, D, E, F, and G sheets. In some aspects, the monobody disclosed herein may comprise at least seven sheets, designated N-terminus to C-terminus A, B, C, D, E, F and G strands wherein each sheet is connected by a loop region wherein the loop regions are designated N-terminus to C-terminus, AB, BC, CD, DE, EF, and FG. In some aspects, the monobody disclosed herein comprises, from N-terminus to C-terminus, a sheet, an AB loop, a B sheet, a BC loop, a C sheet, a CD loop, a D sheet, an DE loop, a E sheet, a EF loop, a F sheet; a FG loop; and a G sheet. Any or all of loops AB, BC, CD, DE, EF and FG may participatein target binding. The BC, DE, and FG loops are both structurally and functionally analogous to the complementarity determining regions (CDRs) from immunoglobulins. (See Figures IB and 1C, Chandler PG et al., Cells. 2020 Mar 4;9(3):610).

[0075] Accordingly, in some aspects, the NR4A3 monobody disclosed herein comprises a BC loop, an DE loop, and a FG loop; with at least one loop selected from the BC loop, the DE loop, and the FG loop with an altered amino acid sequence relative to the sequence of the corresponding loop of the wild-type human Fn3 domain. In some aspects, the BC and FG loops are altered, and in some aspects, the BC, DE, and FG loops are altered, i.e., the Fn3 domains comprise non-naturally occurring loops. In some aspects, one or more of the AB, CD EF loops are altered.

[0076] Tables 1 and 2 provide the exemplary monobodies and regions therein.TABLE 1 exemplary NR4A3 monobodiesNR4A3 NR4A3 SEQ NR4A3 SEQ Monobody SEQ ID Monobody MnB ID Monobody ID MnB A NO B NO MnB C NO N- VSSVPTKL 7 VSSVPTKL 7 VSSVPTKL 7 terminalA sheet EWAAT 8 EWAAT 8 EWAAT 8 AB loop PTSLLISWDA 9 PTSLLISWDA 9 PTSLLISWDA 9 B sheet SLLISWDA 10 SLLISWDA 10 SLLISWDA 10 BC Loop GRMWPVT 3 SWYVRVL 4 SWFRRVF 101 C sheet YYRITYGET 11 YYRITYGET 11 YYRITYGET 11 CD loop GGNSP 12 GGNSP 12 GGNSP 12 D sheet VQEFTV 13 VQEFTV 13 VQEFTV 13 DE Loop PGTKS 5 PGWYH 6 PGWYT 102 E sheet TATI 14 TATI 14 TATI 14 EF loop SGLKPG 15 SGLKPG 15 SGLKPG 15 F sheet VDYTITVYA 16 VDYTITVYA 16 VDYTITVYA 16 FG Loop FAGFFHRLHY 1 LNGYKWYH 2 FRGTTNLKST 103 G sheet PISINYRT 17 PISINYRT 17 PISINYRT 17

[0077] In some aspects, a BC loop of the NR4A3 monobody disclosed herein comprises the sequence of the first underlined portion from the N-terminus of any one of the amino acid sequences as shown in SEQ ID NO: 21-SEQ ID NO: 34 or any one of the amino acid sequences provided in Table 2. For example, a BC loop may comprise the sequence GRMWPVT (SEQ IDNO: 3), the sequence SWYVRVL (SEQ ID NO: 4), or the sequence SWFRRVF (SEQ ID NO: 101).

[0078] In some aspects, a DE loop of the NR4A3 monobody disclosed herein comprises the sequence of the second underlined portion from the N-terminus of any one of the amino acid sequences as shown in SEQ ID NO: 21-SEQ ID NO: 34 or any one of the sequences as shown in Table 2. For example, a DE loop may comprise the sequence PGTKS (SEQ ID NO: 5), the sequence PGWYH (SEQ ID NO: 6), or the sequence PGWYT (SEQ ID NO: 102).

[0079] In some aspects, a FG loop of the NR4A3 monobody disclosed herein comprises the sequence of the third underlined portion from the N-terminus of any one of the amino acid sequences as shown in SEQ ID NO: 21-SEQ ID NO: 34 or any one of the sequences as shown in Table 2. For example, a BC loop may comprise the sequence FAGFFHRLHY (SEQ ID NO: 1, the sequence LNGYKWYH (SEQ ID NO: 2), or the sequence FRGTTNLKST (SEQ ID NO: 103).

[0080] In some aspects, the NR4A3 monobody disclosed herein comprises any one of the amino acid sequences as shown in Table 2 (e.g., SEQ ID NO: 21 to SEQ ID NO: 34).TABLE 2 exemplary NR4A3 monobody amino acid sequencesMonobody amino acid sequenceNR4A3 (BC loop, DE loop, FG loop, from N terminus to C terminus, are shown inMonobody underline) SEQ ID NO:MnB A VSSVPTKLEWAATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVOE 21FTVPGTKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRTMnB B VSSVPTKLEWAATPTSLLISWDASWYVRVLYYRITYGETGGNSPVOE 22FTVPGWYHTATISGLKPGVDYTITVYALNGYKWYHPISINYRTMnB C VSSVPTKLEVVAATPTSLLISWDASWFRRVFYYRITYGETGGNSPVQEF 23TVPGWYTTATISGLKPGVDYTITVYAFRGTTNLKSTPISINYRTMnB D VSSVPTKLEWAATPTSLLISWDAGIRWTVFYYRITYGETGGNSPVQEF 24TVPGKPRTATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRTMnB E VSSVPTKLEWAATPTSLLISWDAGFWYRVYYYRITYGETGGNSPVOE 25FTVPGWYATATISGLKPGVDYTITVYALGGRSROPISINYRTMnB F VSSVPTKLEWAATPTSLLISWDAGAYYTVYYYRITYGETGGNSPVOE 26FTVPGSTWTATISGLKPGVDYTITVYAFAGFFHRLHSPISINYRTMnB G VSSVPTNLEWAATPTSLLISWDAGAYYTVYYYRITYGETGGNSPVOE 27FTVPGSTWTATISGLKPGVDYTITVYAFAGFFHRLHSPISINYRTMnB H VSSVPTKLEVVAATPTSLLISWDAGFYYRVFYYRITYGETGGNSPVOEF 28TVPGWYHTATISGLKPGVDYTITVYAFNGYKWYHPISINYRTMnB I VSSVPTKLEVVAATPTSLLISWDASWFLRVMYYRITYGETGGNSPVOE 29FTVPGWYSTATISGLKPGVDYTITVYALFGAYSYPRQPISINYRTMnB J VSSVPTKLEWAATPTSLLISWDAGFYHRVIYYRnYGETGGNSPVOEF 30TVPGRRATATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRTMonobody amino acid sequenceNR4A3 (BC loop, DE loop, FG loop, from N terminus to C terminus, are shown inMonobody underline) SEQ ID NO:MnB K VSSVPTKLEVVAATPTSLLISWDAGAYHRVYYYRITYGETGGNSPVOE 31FTVPGTDVTATISGLKPGVDYTITVYAFQGFWHRLHTPISINYRTMnB L VSSVPTKLEVVAATPTSLLISWDAPHSGVQYYRITYGETGGNSPVQEFT 32VPGTSSTATISGLKPGVDYTITVYAFRGFYHRLHSPISINYRTMnB M VSSVPTKLEVVAATPTSLLISWDASWFLRVMYYRITYGETGGNSPVOE 33FTVPGWYHTATISGLKPGVDYTITVYALNGRRSOLKPHTPISINYRTMnB N VSSVPTKLEWAATPTSLLISWDAGWYWRVYYYRVTYGETGGNSPVO 34EFTVPGDLQTATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRT

[0081] In some aspects, the BC, DE, and FG loop regions disclosed herein can be generally described according to consensus sequences.

[0082] For example, a BC loop can be generally described as comprising (i) a consensus sequence GX1X2X3X4VX5 (SEQ ID NO: 35) where Xi, X2, and X3 is any amino acid, Xus P, R, or T, and X5is any amino acid; or (ii) a consensus sequence SWX1X2RVX3 (SEQ ID NO: 36) where XI is Y or F; X2 is V, L, or R; and X3 is L, F, or M. This consensus sequence is exemplified by BC loops shown in Table 2 except for the BC loop defined by SEQ ID NO: 32.

[0083] In some aspects, a DE loop can be generally described as comprising a consensus sequence PGXeXvXs (SEQ ID NO: 37) where Xe, X7, and Xs is any amino acid. This consensus sequence is exemplified by BC loops of the sequences shown in Table 2. In some aspects, Xe is K, W, R, S, T, or D; X7 is K, Y, P, T, R, D, or S; or Xs is S, H, T, R, Y, W, A, V, Q or T. In some aspects, Xe is K or W; X7 is P or Y; or Xs is R, T, or A.

[0084] In some aspects, a FG loop can be generally described as comprising (i) a consensus sequence FX9GFX10HRLHX11 (SEQ ID NO: 38) where X9 is A, R, or Q; X10 is an aromatic residue optionally selected from Y, F, or W; and X11 is Y, S, or T; or (ii) a consensus sequence X9NGYKWYH (SEQ ID NO: 39) where X9is L or F; (iii) a consensus sequence FRGTTNLKST (SEQ ID NO: 103); or (iv) a consensus sequence LFGAYSYPRQ (SEQ ID NO: 104). In some aspects, the FG loop comprises the consensus sequence FX9GFX10HRLHX11 (SEQ ID NO: 38) wherein X9 is alanine (A).

[0085] Accordingly, in some aspects, the NR4A3-binding monobody disclosed herein comprises an FG loop, a DE loop, and a BC loop according to consensus sequences provided herein.

[0086] In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35) or SWX1X2RVX3 (SEQ ID NO: 36),a DE loop having the sequence PGXeXvXx (SEQ ID NO: 37), and an FG loop having the sequence FX9GFX10HRLHX11 (SEQ ID NO: 38), the sequence X9NGYKWYH (SEQ ID NO: 39), or the sequence FRGTTNLKST (SEQ ID NO: 103), as defined above. In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35) or SWX1X2RVX3 (SEQ ID NO: 36), a DE loop having the sequence PGX6X7X8(SEQ ID NO: 37), and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1) as provided above. In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35) or SWX1X2RVX3 (SEQ ID NO: 36), as defined above, a DE loop having the sequence PGTKS (SEQ ID NO: 5), the sequence PGWYH (SEQ ID NO: 6), or the sequence PGWYT (SEQ ID NO: 102); and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1), the sequence LNGYKWYH (SEQ ID NO: 2), or the sequence FRGTTNLKST (SEQ ID NO: 103). In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GRMWPVT (SEQ ID NO: 3), the sequence SWYVRVL (SEQ ID NO: 4), or the sequence of SWFRRVF (SEQ ID NO: 101), a DE loop having the sequence PGTKS (SEQ ID NO: 5), the sequence PGWYH (SEQ ID NO: 6), or the sequence PGWYT (SEQ ID NO: 102); and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1), the sequence LNGYKWYH (SEQ ID NO: 2) , or the sequence FRGTTNLKST (SEQ ID NO: 103).

[0087] In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35), a DE loop having the sequence PGX6X7X8 (SEQ ID NO: 37), and an FG loop having the sequence FX9GFX10HRLHX11 (SEQ ID NO: 38) as defined above. In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35), a DE loop having the sequence PGXeXvXx (SEQ ID NO: 37), and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1) as provided above. In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence GX1X2X3X4VX5 (SEQ ID NO: 35) as defined above, a DE loop having the sequence PGTKS (SEQ ID NO: 5), and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1). In some aspects, the NR4 A3 -binding monobody disclosed herein comprises a BC loop having the sequence GRMWPVT (SEQ ID NO: 3), a DE loop having the sequence PGTKS (SEQ ID NO: 5), and an FG loop having the sequence FAGFFHRLHY (SEQ ID NO: 1).

[0088] In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence SWX1X2RVX3 (SEQ ID NO: 36), a DE loop having the sequencePGX6X7X8(SEQ ID NO: 37), and an FG loop having the sequence X9NGYKWYH (SEQ ID NO: 39) or the sequence FRGTTNLKST (SEQ ID NO: 103), as provided above. In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence SWX1X2RVX3 (SEQ ID NO: 36), a DE loop having the sequence PGX6X7X8(SEQ ID NO: 37), as defined above, and an FG loop having the sequence LNGYKWYH (SEQ ID NO: 2) or the sequence FRGTTNLKST (SEQ ID NO: 103). In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence SWX1X2RVX3 (SEQ ID NO: 36) as defined above, a DE loop having the sequence PGWYH (SEQ ID NO: 6), and an FG loop having the sequence LNGYKWYH (SEQ ID NO: 2) or the sequence FRGTTNLKST (SEQ ID NO: 103). In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence SWYVRVL (SEQ ID NO: 4), a DE loop having the sequence PGWYH (SEQ ID NO: 6), and an FG loop having the sequence LNGYKWYH (SEQ ID NO: 2). In some aspects, the NR4A3-binding monobody disclosed herein comprises a BC loop having the sequence SWFRRVF (SEQ ID NO: 101), a DE loop having the sequence PGWYT (SEQ ID NO: 102), and an FG loop having the sequence FRGTTNLKST (SEQ ID NO: 103).

[0089] Accordingly, in some aspects, the amino acid sequence of the NR4A3 monobody disclosed herein (e.g., the sequences shown in Table 2) can be represented by one of the following consensus sequences:VSSVPTKLEVVAATPTSLLISWDAGX1X2X3X4VX5YYRITYGETGGNSPVQEFTVPGX6 X7X8TATISGLKPGVDYTITVYAFX9GFXIOHRLHXIIPISINYRT (SEQ ID NO: 105); or VSSVPTKLEVVAATPTSLLISWDASWX1X2RVX3YYRITYGETGGNSPVQEFTVPGX6X7X8TATISGLKPGVDYTITVYAX9NGYKWYHPISINYRT (SEQ ID NO: 106); or VSSVPTKLEVVAATPTSLLISWDASWX1X2RVX3YYRITYGETGGNSPVQEFTVPGX6X7X8TATISGLKPGVDYTITVYAFRGTTNLKSTPISINYRT (SEQ ID NO: 107).

[0090] In the foregoing sequences, the BC loop, DE loop, FG loop, from N terminus to C terminus, are shown in underline. In some embodiments, the NR4A3 monobody disclosed herein comprises the sequence of any one of SEQ ID NO: 105, SEQ ID NO: 106, and SEQ ID NO: 107. In some aspects, for the consensus sequence of SEQ ID NO: 105, XI is R, I, F, A, or W; X2 is M, R, W, A, or Y; X3 is W, Y, or H; X4 is P, T, or R; X5 is T, F, Y, or I; X6 is T, K, W, S, R, or D; X7 is K, P, T, D, or S; X8 is S, R, W, V, or Q; X9 is A, R, or Q; XI 0 is F, Y, or W; and XI 1 is Y, S, or T. In some aspects, for the consensus sequence of SEQ ID NO: 106, XI is Y or F; X2 is V, Y, or L; X3 is L, F, or M; X6 is W; X7 is Y; X8 is H or S; and X9 is L or F. In some aspects, forthe consensus sequence of SEQ ID NO: 107, XI is F; X2 is R; X3 is F; X6 is W; X7 is Y; and X8 is T.

[0091] In some aspects, the FG loop comprises the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 103. In some aspects, the BC loop comprises the amino acid sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 101. In some aspects, the DE loop comprises the amino acid sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 102.

[0092] In some aspects, the NR4A3 monobody disclosed herein comprises a FG loop, a DE loop, and a BC loop comprising (i) the amino acid sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 3, respectively, (ii) the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 4, respectively, or (iii) the amino acid sequences as set forth in SEQ ID NO: 103, SEQ ID NO: 102, and SEQ ID NO: 101, respectively.

[0093] In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 21. In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 22. In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 23.

[0094] In some aspects, the NR4A3 monobody disclosed herein binds to a ligand binding domain (LBD) of the NR4A3. In some aspects, the LBD of the NR4A3 disclosed herein comprises amino acids 394-626 of SEQ ID NO: 91.

[0095] In some aspects, the NR4A3 monobody disclosed herein does not cross-react with NR4A1 or NR4A2. In some aspects, the NR4A3 monobody disclosed herein does not specifically bind to NR4A1 or NR4A2. In some aspects, the NR4A1 comprises the amino acid sequence as set forth in any one of SEQ ID NOs: 96-98. In some aspects, the NR4A2 comprises the amino acid sequence as set forth in SEQ ID NO: 94 or SEQ ID NO: 95.

[0096] In some aspects, the NR4A3 monobody disclosed herein has a KD less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 55 nM, less than about 50 nM, less than about 45 nM, less than about 40 nM, less than about 35 nM, less than about 30 nM, less than about 25 nM, less than about 20 nM, less than about 19 nM, less than about 18 nM, less than about 17 nM, less than about 16 nM, less than about 15 nM, less than about 14 nM, less than about 13 nM, less than about 12 nM, less than about 11 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, or less than about 1 nM.

[0097] In some aspects, the NR4A3 monobody disclosed herein has a KD of about 100 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 90 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 100 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 80 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 70 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 60 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 55 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 50 nM, of about 45 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 40 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 35 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 30 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 25 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of 20 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 15 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 10 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 9 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 8 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 7 nM. In some aspects, the NR4A3 monobody disclosed herein has a KD of about 6 nM or of about 5 nM.

[0098] In some aspects, the NR4A3 monobody disclosed herein further comprises an AB loop, a CD loop, and an EF loop. In some aspects, the AB loop comprises any one of the amino acid sequence as set forth in SEQ ID NO: 9. In some aspects, the AB loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequence as set forth in SEQ ID NO: 9. In some aspects, the AB loop comprises the amino acid sequence as set forth in SEQ ID NO: 9. In some aspects, the AB loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence as set forth in SEQ ID NO: 9.

[0099] In some aspects, the CD loop comprises any one of the amino acid sequence as set forth in SEQ ID NO: 12. In some aspects, the CD loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequence as set forth in SEQ ID NO: 12. In some aspects, the CD loop comprises the amino acid sequence as set forth in SEQ ID NO: 12. In some aspects, the CD loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequence as set forth in SEQ ID NO: 12.

[0100] In some aspects, the EF loop comprises any one of the amino acid sequence as set forth in SEQ ID NO: 15. In some aspects, the EF loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequence as set forth in SEQ ID NO: 15. In some aspects, the EF loop comprises the amino acid sequence as set forth in SEQ ID NO: 15. In some aspects, the EF loop comprises the amino acid sequence as set forth in SEQ ID NO: 15. In some aspects, the CD loop comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequence as set forth in SEQ ID NO: 15.

[0101] In some other aspects, one or more of an AB loop, a CD loop, and an EF loop of the NR4A3 monobody disclosed herein may be derived from el0-FN3 or functional variants thereof, FN3con or functional variants thereof, and Tn3 or functional variants thereof.

[0102] In some aspects, the NR4A3 monobody further comprises one or more beta strand domains comprising A sheet, B sheet, C sheet, D sheet, E sheet, F sheet, and / or G sheet. The sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across one or more of seven regions (A, B, C, D, E, F, and G sheets) relative to the corresponding amino acids shown in SEQ ID NO: 20. In some aspects, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all seven beta strand regions relative to the corresponding amino acids shown in SEQ ID NO: 20.

[0103] In some other aspects, the beta strand domains comprising A sheet, B sheet, C sheet, D sheet, E sheet, F sheet, and / or G sheet of the NR4A3 monobody disclosed herein may be derived from el0-FN3 or functional variants thereof, FN3con or functional variants thereof, and Tn3 or functional variants thereof.

[0104] In some aspects, the A sheet comprises any one of the amino acid sequences as set forth in SEQ ID NO: 8. In some aspects, the A sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 8. In some aspects, the A sheet comprises the amino acid sequence as set forth in SEQ ID NO: 8. In some aspects, the A sheet comprises an amino acid sequence having one, two, three, four, five, or six amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 8. In some aspects, the A sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 8.

[0105] In some aspects, the B sheet comprises the amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the B sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 10. In some aspects, the B sheet comprises the amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the B sheet comprises an amino acid sequence having one, two, three, four, five, six, seven or eight amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 10. In some aspects, the B sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 10.

[0106] In some aspects, the C sheet comprises the amino acid sequence as set forth in SEQ ID NO: 11. In some aspects, the C sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 11. In some aspects, the C sheet comprises the amino acid sequence as set forth in SEQ ID NO: 11. In some aspects, the C sheet comprises an amino acid sequence having one, two, three, four, five, six, seven, eight, or nine amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 11. In some aspects, the C sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 11.

[0107] In some aspects, the D sheet comprises the amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the D sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 13. In some aspects, the D sheet comprises the amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the D sheet comprises an amino acid sequence having one, two, three, four, five, or six amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 13. In some aspects, the D sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 13.

[0108] In some aspects, the E sheet comprises the amino acid sequence as set forth in SEQ ID NO: 14. In some aspects, the E sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 14. In some aspects, the E sheet comprises the amino acid sequence as set forth in SEQ ID NO: 14. In some aspects, the E sheet comprises an amino acid sequence having one, two, three, or four amino acid substitutions, deletions, and / or insertions to the amino acidsequence corresponding to SEQ ID NO: 14. In some aspects, the E sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 14.

[0109] In some aspects, the F sheet comprises the amino acid sequence as set forth in SEQ ID NO: 16. In some aspects, the F sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 16. In some aspects, the F sheet comprises the amino acid sequence as set forth in SEQ ID NO: 16. In some aspects, the F sheet comprises an amino acid sequence having one, two, three, four, five, six, seven, eight, or nine amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 16. In some aspects, the F sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 16.

[0110] In some aspects, the G sheet comprises the amino acid sequence as set forth in SEQ ID NO: 17. In some aspects, the G sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 17. In some aspects, the G sheet comprises the amino acid sequence as set forth in SEQ ID NO: 17. In some aspects, the G sheet comprises an amino acid sequence having one, two, three, four, five, six, seven, or eight amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 17. In some aspects, the G sheet comprises an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 17.[OHl] In some aspects, the NR4A3 monobody further comprises an N terminal sequence comprising the amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the N terminal sequence comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to any one of the amino acid sequences as set forth in SEQ ID NO: 7. In some aspects, the NR4A3 monobody further comprises an N terminal sequence comprising the amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the NR4A3 monobody further comprises an N terminal sequence comprising an amino acid sequence having one, two, three, four, five, six, seven, or eight amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 7. In some aspects, the NR4A3 monobody further comprises an N terminal sequence comprising an amino acid sequence having one or two amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 7.

[0112] In some aspects, the NR4A3 monobody comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to any one of the amino acid sequences as set forth in SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34, , or any one of the amino acid sequences set forth in Table 2.

[0113] In some aspects, the NR4A3 monobody comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to (i) the amino acid sequence as set forth in SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23. In some aspects, the NR4A3 monobody disclosed herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 21. In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 21. In some aspects, the NR4A3 monobody disclosed herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 22. In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 22. In some aspects, the NR4A3 monobody disclosed herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 23. In some aspects, the NR4A3 monobody disclosed herein comprises the amino acid sequence as set forth in SEQ ID NO: 23.

[0114] In some aspects, provided herein is a composition comprising the NR4A3 monobody. In some aspects, the composition comprising the NR4A3 monobody further comprises a function domain. In some aspects of the compositions of the present disclosure, the composition further comprises a functional domain. In some aspects, the functional domain comprises one or more of a degrader, a kinase, a phosphatase, and an epigenetic modifier.

[0115] In some aspects, the NR4A3 monobody is fused to one or more heterologous moieties, e.g., a heterologous polypeptide. In some aspects, the heterologous moiety can be a halflife extending moiety. In some aspects, the heterologous polypeptide fused to the NR4A3 monobody can degrade the NR4A3 protein. In some aspects, the heterologous polypeptide, e.g., a degrader.II. B. Degrader

[0116] The present disclosure provides a polypeptide comprising a functional domain that is capable of degrading a target heterologous protein (e.g., a protein of a nuclear receptor subfamily 4 group A (NR4A) family) (also referred as “degrader”, “engineered degrader domain”, or “chimeric degrader” elsewhere herein).

[0117] In some aspects, the NR4A3 monobody may be fused with a degrader disclosed herein. In some aspects, a degrader may be fused to a heterologous moiety. In some aspects, the heterologous moiety can specifically binds to NR4A3. In some aspects, a moiety that binds to NR4A3 and fused to the degrader disclosed herein can be any NR4A3 binding moiety, e.g., antibody or antigen binding portion thereof, nanobody (e.g., VHH), synthetic protein, or monobody, e.g., any NR4A3 binding moiety known in the art. In some aspects, the protein degradation may be mediated by the ubiquitin proteasome system (UPS). Various degraders or functional domains thereof known in the art may be used with the degrader, fusion protein, or composition disclosed herein.

[0118] In some aspects, a polypeptide comprising an NR4A3 monobody disclosed herein further comprises a degrader (referred as the “NR4A3 monobody-degrader fusion” or “engineered protein regulator” elsewhere herein). The NR4A3 monobody-degrader fusion can comprise from N-terminus to C-terminus (a) an NR4A3 monobody and (b) a degrader or from N-terminus to C-terminus (a) a degrader and (b) an NR4A3 monobody. In some aspects, the NR4A3 monobodydegrader fusion can comprise a linker positioned between the degrader and the NR4A3 monobody.

[0119] In some aspects of the compositions disclosed herein, the composition further comprises a functional domain. In some aspects, the functional domain comprises a degrader. Cullin 3-based E3 ubiquitin ligase complex targets specific proteins for ubiquitin-mediated proteasomal degradation. A degron may bind to the substrate recognition domain of the Ubiquitin E3 ligase complex in a shallow groove. Accordingly, in some aspects, the degrader comprises a functional domain from a ligase-binding domain (e.g., an E3 ligase-binding domain). In some aspects, the degrader comprises a functional domain from a cullin-binding domain. In some aspects, the cullin-binding domain comprises a functional domain from one or more of Sphingosine kinase 1 (ski), elongin-B (ELOB) / elongin-C (EEOC), BTB / POZ domain-containing protein (BTBD), and DNA damage-binding protein 1 (DDB1).

[0120] In some aspects, the degrader comprises a function domain from (a) LNX1 (Ligand of Numb-protein X 1), RNF4 (RING finger protein 4), RNF43 (RING finger protein 43), RNF128 (RING finger protein 128), ZNRF3 (Zinc And Ring Finger 3), MARCHS (Membrane-associatedRING-CH protein VIII), LRG1 (Leucine-rich alpha-2-glycoprotein), NEDD4 (Neural precursor cell expressed developmentally down-regulated protein 4), SOCS2 (Suppressor of cytokine signaling 2), CHIP (Carboxy terminus of HspVO-interacting protein), SPOP (Speckle-type POZ protein), FBXW7 (F- box / WD repeat-containing protein 7), FBXW1A (F-box / WD repeatcontaining protein 1A), FBXL12 (F-box / LRR-repeat protein 12), EEOC (Elongin-C), TRAF6 (TNF receptor-associated factor 6), VHL (von Hippel-Lindau disease tumor suppressor) or any functional fragment thereof; or (b) LNX1, RNF4, RNF43 or any functional fragment thereof; or (c) LNX1 or any functional fragment thereof; or (d) RNF4 or any functional fragment thereof; or (e) RNF43 or any functional fragment thereof; or (f) FBXL12 or any functional fragment thereof.

[0121] In some aspects, the composition disclosed herein further comprises a functional domain. In some aspects, the functional domain comprises a sequence isolated or derived from one or more of ABTB1 (Ankyrin repeat and BTB / POZ domain-containing protein 1), ASB1 (Ankyrin repeat and SOCS box protein 1), ASB6 (Ankyrin repeat and SOCS box protein 6), CHIP, GISH (Cytokine-inducible SH2-containing protein), CRBN (Protein cereblon), DCAF15 (DDB1- and CUL4-associated factor 15), DDB2 (DNA damage-binding protein 2), EID1 (EP300-interacting inhibitor of differentiation 1), EEOC, FBW1A, FBXL12, FBXL14 (F-box / LRR- repeat protein 14, FBXL15 (F-box / LRR-repeat protein 15), FBXL2 (F-box / LRR-repeat protein 2), FBX024 (F-box only protein 24), FBX03 (F-box only protein 3), FBXO40 (F-box only protein 40, FBX06 (F-box only protein 6, FBXW5 (F-box / WD repeat-containing protein 5), FBXW7 (F- box / WD repeatcontaining protein 7), FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B), GABARAP (Gamma-aminobutyric acid receptor-associated protein, GABARAPL2 (Gamma-aminobutyric acid receptor-associated protein-like 2), GAN (Gigaxonin), GET4 (Golgi to ER traffic protein 4 homolog), GID8 (Glucose-induced degradation protein 8 homolog), GMCL1 (Germ cell-less protein-like 1), HDAC1 (Histone deacetylase 1), ISG15 (Ubiquitin-like protein ISG15), KBTBD7 (Kelch repeat and BTB domain-containing protein 7), KLHDC2 (Kelch domain- containing protein 2), KLHL11 (Kelch-like protein 11), KLHL12 (Kelch-like protein 12), KLHL23 (Kelch-like protein 23), KLHL40 (Kelch-like protein 40, KLHL6 (Kelch-like protein 6), LAPTM5 (Lysosomal-associated transmembrane protein 5, LDOC1 (Protein LDOC1), LNX1, LY6D (Lymphocyte antigen 6D), LYPD3 (Ly6 / PLAUR domain-containing protein 3), MAGEA2B (Melanoma-associated antigen 2), MAP1LC3A (Microtubule-associated proteins 1A / 1B light chain 3A), MTCH1 (Mitochondrial carrier homolog 1), MYLIP (Myosin regulatory light chain interacting protein), NDFIP2 (E3 ubiquitin-protein ligase NEDD4-like), NEDD4, NHLRC1 (NHL repeat- containing protein 1), OTUB1 (Ubiquitin thioesterase OTUB1), PCGF3(Polycomb group RING finger protein 3), PIAS3 (E3 SUMO-protein ligase PIAS3), PIAS4 gamma (E3 SUMO-protein ligase PIAS4), PJA1 (E3 ubiquitin-protein ligase Praja-1), PPAR gamma (Peroxisome proliferator- activated receptor alpha), PRR20A (Proline-rich protein 20A), PSMD2 (Proteasome 26S Subunit Ubiquitin Receptor, Non-ATPase 2), RAB40AL (Ras-related protein Rab- 40A-like), RNF115 (RING finger protein 115), RNF125 (RING finger protein 125), RNF126(RING finger protein 126), RNF130 (RING finger protein 130), RNF138 (RING finger protein 138), RNF144A (RING finger protein 144A), RNF144B (RING finger protein 144B), RNF150 (RING finger protein 150), RNF166 (RING finger protein 166), RNF181 (RING finger protein 181), RNF182 (RING finger protein 182), RNF183 (RING finger protein 183), RNF185 (RING finger protein 185), RNF24 (RING finger protein 124), RNF4, RNF41 (RING finger protein 41), RNF43, RNF8 (RING finger protein 8), RTL8C (Retrotransposon Gag-like protein 8C), SKP2 (S-phase kinase-associated protein 2), SOCS1 (suppressor of cytokine signaling 1), SOCS2 (suppressor of cytokine signaling 2), SOC S3 (suppressor of cytokine signaling 3), SOCS5 (suppressor of cytokine signaling 5), SPOP, SPSB2 (SPRY domain-containing SOCS box protein 2), SPSB4 (SPRY domain-containing SOCS box protein 4), SQSTM1 (Sequestosome-1), TEX19 (Testis-expressed protein 19), TRAF2 (TNF receptor-associated factor 2), TRAF6, Triml3 (E3 ubiquitin-protein ligase TRIM13), TRIM31 (E3 ubiquitin-protein ligase TRIM31), TRIM39 (E3 ubiquitin-protein ligase TRIM39), TRIM49 (E3 ubiquitin-protein ligase TRIM49), TRIMS (E3 ubiquitin-protein ligase TRIMS), UBC9 (SUMO-conjugating enzyme UBC9), UBE2A (Ubiquitin-conjugating enzyme E2 A), UBE2B (Ubiquitin-conjugating enzyme E2 B), UBE2D1 (Ubiquitin-conjugating enzyme E2 DI), UBE2D4 (Ubiquitin-conjugating enzyme E2 D4), UCHL1 (Ubiquitin carboxyl- terminal hydrolase isozyme El), VHL, and ZER1 (Protein zer-1 homolog).

[0122] In some aspects, the degrader comprises a functional domain from SPOP, FBXL12, SOCS2, RNF8, 3xUb(K48R), ABTB1, ASB1, ASB6, c-cbl, cbl-b, CHIP, CISH, CRBN, DCAF15, DDB2, EID1, ELOC, FBW1A, FBXL2, FBXL14, FBXL15, FBXO24, FBXO3, FBXO40, FBXO6, FBXW5, FBXW7, FCGR3B, GABARAP, GABARAPL2, GAN, GET4, GID8, GMCL1, HDAC1, ISG15, KBTBD7, KLHDC2, KLHL11, KLHL12, KLHL23, KLHL40, KLHL6, LAPTM5, LDOC1, LNX1, LY6D, LYPD3, MAGEA2B, MAP1LC3A, March8, MTCH1, MYLIP, NDFIP2, NEDD4, NHLRC1, OTUB1, PCGF3, PIAS3, PIAS4 (gamma), PJA1, PPARgamma, PRAME, PRR20A, PSMD2, RAB40AL, RCHY1, RNF115, RNF123, RNF123 truncated, RNF125, RNF126, RNF130, RNF138, RNF144A, RNF144B, RNF150, RNF166, RNF181, RNF182, RNF183, RNF185, RNF24, RNF4, RNF41, RNF43, RTL8C, SKP1, SKP2, SOCS1, SOCS3, SOCS5, SPSB2, SPSB4, SQSTM1, TEX19, TRAF2, TRAF6, Triml3, TRIM31,TRIM39, TRIM49, TRIM5, UBC9, UBE2A, UBE2B, UBE2D1, UBE2D4, UCHL1, VHL, ZER1, or any combination thereof.

[0123] SPOP (Speckle-type POZ protein) is a substrate adaptor for the Cullin 3-based E3 ubiquitin ligase complex, which targets specific proteins for ubiquitin-mediated proteasomal degradation. SPOP binds to specific substrate proteins via its MATH domain, recognizing Ser / Thr-rich degron motifs and recruting the Cullin 3 -based E3 ligase complex. The recruited complex facilitates polyubiquitination of the substrate proteins, and the ubiquitinated substrates are then recognized and degraded by the proteasome (e.g., 26S proteasome). Accordingly, in some aspects, the degrader comprises a functional domain from SPOP.

[0124] In some aspects, the degrader comprises a functional domain from SOCS2. In some aspects, the degrader comprises a functional domain from FBXL12. In some aspects, the degrader comprises a functional domain from RNF8.

[0125] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 167 to 374 of SPOP, amino acids 143 to 198 of SOCS2, amino acids of FBXL12, NLS (CaV), SKP1(L), SKP2(L), amino acids of SOCS2box, amino acids of SOCS1NLS, amino acids of RNF8, amino acids of EloC(WT), amino acids 161 to 198 of SOCS2box, amino acids 10-17 ofEloB(WT), amino acids ofEloC(M3), amino acids amino acids of ELoC (WT), amino acids of UBE2B, or any combination thereof.

[0126] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 40 (full-length wild type SPOP).

[0127] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 167 to 374 of the full-length wild type SPOPas shown in SEQ ID NO: 40. In some aspects, the degrader comprises amino acids 167 to 374 of the full-length wild type SPOP as shown in SEQ ID NO: 40. In some aspects, the degrader comprises SEQ ID NO: 41.

[0128] In some aspects, the degrader comprises amino acids 143-198 of the full length SOCS2. In some aspects, the degrader comprises amino acids 143-198 of SEQ ID NO: 69. In some aspects, the degrader comprises SEQ ID NO: 53 or SEQ ID NO: 46.

[0129] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%,or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 46.

[0130] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 47. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 47.

[0131] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 48. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 48.

[0132] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 49. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 49.

[0133] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 50. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 50.

[0134] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 51. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 51.

[0135] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 52. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 52.

[0136] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 53. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 53.

[0137] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%,or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 54. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 54.

[0138] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 55. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 55.

[0139] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 56. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 56.

[0140] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 57. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 57.

[0141] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 58. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 58.

[0142] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 59. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 59.

[0143] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 60. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 60.

[0144] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 61. In some aspects, the degrader comprises the amino acid sequence set forth in SEQ ID NO: 61.

[0145] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 178-374 of SEQ ID NO: 40.

[0146] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 167-355 of SEQ ID NO: 40

[0147] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acid 178-295 and 358-374 of SEQ ID NO: 40.

[0148] In some aspects, the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acid 178-329 and 358-374 of SEQ ID NO: 40.

[0149] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to any one of the amino acid sequences according to SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51. In some aspects, provided herein is a polypeptide comprising any one of the amino acid sequences according to SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51. In some aspects, provided herein is a fusion protein comprising the polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein. In some aspects, the polypeptide is a chimeric degrader capable of degrading a target heterologous protein. In some aspects, the polypeptide is an engineered degrader capable of degrading a target heterologous protein.

[0150] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 44. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 44. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0151] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 45. In some aspects, provided herein is a polypeptide comprising the aminoacid sequence set forth in SEQ ID NO: 45. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0152] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 46. In some aspects, provided herein is a fusion protein comprising the polypeptide and one or more heterologous functional domain disclosed herein.

[0153] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 47. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 47. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0154] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 48. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 48. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0155] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 49. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 49. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0156] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence setforth in SEQ ID NO: 50. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 50. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0157] In some aspects, provided herein is a polypeptide comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 51. In some aspects, provided herein is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 51. In some aspects, provided herein is a fusion protein comprising said polypeptide and one or more heterologous functional domain disclosed herein. In some aspects, the polypeptide is capable of degrading a target heterologous protein.

[0158] In some aspects, provided herein is a fusion protein comprising a polypeptide that is capable of degrading a target heterologous protein disclosed herein (or a degrader) and a binding moiety that specifically binds to the heterologous protein. In some aspects, the binding moiety comprises an antibody or antigen binding portion thereof, a monobody or antigen binding portion thereof, a nanobody or antigen binding portion thereof, or any combination thereof. In some aspects, the binding moiety comprises a TAA moiety disclosed herein.

[0159] In some aspects, the heterologous protein comprises an NR4A3. Accordingly, in some aspects, the binding moiety comprises the NR4A3 monobody disclosed herein. In some aspects, the degrader comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 41 to SEQ ID NO: 61.II. C. Exemplary monobody-degrader fusion sequences

[0160] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a degrader that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to any one of the amino acid sequences as set forth in SEQ ID NO: 70 to SEQ ID NO: 85. In some aspects, a fusion protein comprising a monobody disclosed herein with a degrader disclosed herein can be referred to as “an engineered protein regulator” or “an NR4A3 monobody-degrader fusion.”

[0161] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In someaspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 70.

[0162] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 74.

[0163] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75.

[0164] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76.

[0165] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77.

[0166] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78.

[0167] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 79.

[0168] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 80.

[0169] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a RNF8 protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 81.

[0170] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 82.

[0171] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 83.

[0172] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 84.

[0173] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a UBE2B protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 85.

[0174] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at leastabout 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71.

[0175] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72

[0176] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 73.

[0177] In some aspects, provided herein is a fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3. In some aspects, the fusion protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 74.

[0178] In some aspects, the NR4A3 monobody can be placed in the N terminus of the degrader, via an optional linker. In some aspects, the NR4A3 monobody can be placed in the C-terminus of the degrader, via an optional linker.

[0179] In some aspects, the fusion protein disclosed herein further comprises a heterologous moiety. In some aspects, the heterologous moiety may be fused at the C-terminus or at the N-terminus of the amino acid sequence of the NR4A3 monobody disclosed herein. In some aspects, the heterologous moiety comprises a heterologous polypeptide. In some aspects, the NR4A3 monobody and the heterologous moiety are connected via a linker.

[0180] In some aspects, the fusion protein or composition disclosed herein further comprises a cleavage site. In some aspects, the cleavage site is a self-cleaving peptide.II. D. Additional Heterologous Moieties; Heterologous Functional Domains

[0181] In some aspects, the NR4A3 monobody disclosed herein further comprises a heterologous moiety. In some aspects, the heterologous moiety may be fused at the C-terminus or at the N-terminus of the amino acid sequence of the NR4A3 monobody disclosed herein. In someaspects, the heterologous moiety comprises a heterologous polypeptide. In some aspects, the NR4A3 monobody and the heterologous moiety are connected via a linker.

[0182] In some aspects, the heterologous moiety comprises one or more heterologous functional domains (e.g., is or comprises a fusion protein). The fusion may be formed by attaching a heterologous functional domain to either N-terminal end or C-terminal end of the NR4A3 monobody, i.e., an NR4A3 monobody - heterologous functional domain or heterologous functional domain - NR4A3 monobody arrangements.

[0183] In some aspects, the fusion protein disclosed herein further comprises an additional heterologous moiety. In some aspects, the heterologous moiety may be positioned at the C-terminus or at the N-terminus of the amino acid sequence of the NR4A3 monobody disclosed herein. In some aspects, the heterologous moiety may be positioned at the C-terminus or at the N-terminus of the amino acid sequence of the degrader disclosed herein. In some aspects, the heterologous moiety may be positioned at the C-terminus or at the N-terminus of the amino acid sequence of the NR4A3 monobody disclosed herein. In some aspects of the fusion protein disclosed herein, the heterologous moiety may be positioned between the NR4A3 monobody and the degrader.

[0184] In some aspects, the fusion protein or composition disclosed herein further comprises a cleavage site. In some aspects, the cleavage site is a self-cleaving peptide.

[0185] In some aspects, the fusion protein or composition disclosed herein further comprises a nuclear localization sequence (NLS).

[0186] In some aspects, the fusion protein or composition disclosed herein further comprises a FLAG tag.Half-life extending moiety

[0187] In some aspects, the heterologous functional domain may be capable of modifying the intracellular half-life of the NR4A3 monobody. In some aspects, the half-life of the NR4A3 monobody may be increased. In some aspects, the half-life of the NR4A3 monobody may be reduced. In some aspects, the heterologous functional domain may be capable of increasing the stability of the NR4A3 monobody. In some aspects, the heterologous functional domain may be capable of reducing the stability of the NR4A3 monobody.

[0188] Accordingly, in some aspects, the NR4A3 monobody disclosed herein further comprises a half-life extending moiety. In some aspects, the fusion protein disclosed herein further comprises a half-life extending moiety.

[0189] Examples of such a half-life extending moiety include, but not limited to, immunoglobulin Fc and fragments and variants thereof, transferrin, or serum albumin, XTEN, PAS sequences, CTP (28 amino acid C-terminal peptide (CTP) of human chorionic gonadotropin (hCG) with 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin-binding polypeptides, albumin-binding small molecules, or any combination thereof.

[0190] In some aspects, the heterologous moiety comprises an immunoglobulin Fc domain, or a fragment or variant thereof. The Fc domain may be derived from an IgGl subclass; however, other subclasses (e.g., IgG2, IgG3, and IgG4) may also be used. In some aspects, the NR4A3 monobody disclosed herein further comprises polyethylene glycol (PEG). One or more PEG molecules may be attached at different positions on the protein, and such attachment may be achieved by reaction with amines, thiols or other suitable reactive groups. The amine moiety may be, for example, a primary amine found at the N-terminus of a polypeptide or an amine group present in an amino acid, such as lysine or arginine.Linker

[0191] Insertion of linkers between fusion protein domains can increase bioactivity by increasing distance between domains; or improving or restoring folding. Use of a cleavable linker allows releasing active domain. Accordingly, in some aspects, the degrader is linked to the monobody via a linker. In some aspects, the degrader is present at the C terminus of the monobody, optionally via a linker. In some aspects, the degrader is present at the N terminus of the monobody, optionally via a linker.

[0192] In some aspects, the linker comprises one or more of an amino acid, a nucleic acid, a synthetic or non-naturally occurring amino acid, a synthetic or non-naturally occurring nucleotide, and a combination thereof. In some aspects, the linker comprises an amino acid or a synthetic or non-naturally occurring amino acid. In some aspects, the linker or a sequence thereof is flexible. In some aspects, the linker is a non-cleavable linker or a cleavable linker. In some aspects, the linker comprises a flexible linker or a cleavable linker.

[0193] In some aspects, the linker or a sequence thereof comprises Glycine (G) and Serine (S). In some aspects, the linker comprises a sequence of SEQ ID NO: 30-33. In some aspects, the linker comprises a GS linker. In some aspects, the linker comprises any one of SEQ ID NO: 62 to SEQ ID NO: 65. In some aspects, the linker comprises a furin. Additional exemplary linkers are shown in Table 3 below.

[0194] In some aspects, the degrader is linked to the monobody directly.Tumor associated antigen-binding moiety

[0195] In some aspects, the fusion protein disclosed herein further comprises a moiety that binds to a tumor associated antigen (TAA) (“TAA binding moiety”).

[0196] In some aspects, the TAA binding moiety comprises a chimeric antigen receptor (CAR), a T cell receptor (TCR), a TCR mimetic, or any combination thereof. In some aspects, the TAA binding moiety is linked to the N-terminus of the monobody, optionally via a BM linker. In some aspects, the TAA binding moiety is linked to the C-terminus of the monobody, optionally via a BM linker. In some aspects, the TAA binding moiety is linked to the N-terminus of the degrader, optionally via a BM linker. In some aspects, the TAA binding moiety is linked to the N-terminus of the degrader, optionally via a BM linker. In some aspects, the BM linker is a cleavable linker.

[0197] In some aspects, the CAR targets PRAME, CD 19, TRAC, TCRp, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD70, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, ROR1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, S SEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE- Al, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT- 2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.

[0198] In some aspects, the TCR or TCR mimetic targets PRAME, AFP, CD 19, TRAC, TCRP, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, ROR1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1,MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CX0RF61, CD97, CD179a, ALK, Poly sialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT- 2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.II. E. Exemplary compositions

[0199] In some aspects, provided herein is a composition comprising the NR4A3 monobody, the degrader, or the fusion protein disclosed herein.

[0200] In some aspects of the compositions of the disclosure, the composition comprises one or more of SEQ ID NOs: 21 to 34 and 41 to 61, or any one of the sequence as shown in Tables 1 and 2. In some aspects of the compositions of the disclosure, the composition comprises any one of SEQ ID NOs: 70 to 85 or any of the fusion protein sequences as shown in Table 3. In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to any one of the sequence of SEQ ID NOs: 70 to 85 or any of the fusion protein sequences as shown in Table 3.

[0201] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 70. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 70.

[0202] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 71. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 71.

[0203] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 71. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 71.

[0204] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 72. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 72.

[0205] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 73. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 73.

[0206] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 74. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 74.

[0207] In some aspects of the compositions of the disclosure, the composition comprises a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to SEQ ID NO: 75. In some aspects of the compositions of the disclosure, the composition comprises SEQ ID NO: 75.III. Polynucleotides and Vectors

[0208] The disclosure provides a polynucleotide encoding the NR4A3 monobody, the degrader, the fusion protein, or the composition disclosed herein.

[0209] In some aspects, the polynucleotide comprises a regulatory element. In some aspects, the regulatory element comprises a promoter, optionally, wherein the promoter is a constitutive promoter or an inducible promoter. In some aspects, the promoter comprises a minimal promoter. In some aspects, the promoter comprises a constitutive promoter. In some aspects, the constitutive promoter comprises a sequence isolated or derived from a mammalian MND promoter. In some aspects, the promoter comprises an inducible promoter. In some aspects, the inducible promoter comprises a sequence isolated or derived from a mammalian NFkB promoter. Alternatively, or in addition, the regulatory sequence comprises one or more of an enhancer of any sequence (including the sequence encoding an NR4A3 monobody, a degrader, a polypeptide, acomposition or a fusion protein thereof or any other sequence disclosed herein), a silencer of any sequence (including the sequence encoding an NR4A3 monobody, a degrader, a polypeptide, a composition or a fusion protein thereof or any other sequence disclosed herein), a repressor of any sequence (including the sequence encoding an NR4A3 monobody, a degrader, a polypeptide, a composition or a fusion protein thereof or any other sequence disclosed herein), an intron of any gene (including a beta-actin gene), an exon of any gene (including a beta-actin gene), a splice acceptor site of any gene (including a beta-globin gene), an untranslated region, a terminal or inverted repeat sequence, a “TATA box” sequence, a post- transcriptional regulatory element (PRE, including a woodchuck PRE (WPRE)) or any combination thereof.

[0210] Vectors comprising polynucleotides that encode the NR4A3 monobody-degrader fusion protein disclosed herein are provided. Vectors comprising polynucleotides that encode the TAA binding moieties (e.g., CAR or TCR) disclosed herein are also provided. In some aspects, the vectors comprise one or more polynucleotides encoding heavy chains and / or light chains of the CAR or TCR are provided.

[0211] In some aspects, provided herein are a first vector comprising a polynucleotide that encodes the NR4A3 monobody-degrader fusion protein sequence disclosed herein and a second vector comprising a polynucleotide that encodes a CAR. In some aspects, provided herein are a first vector comprising a polynucleotide that encodes the NR4A3 monobody-degrader fusion protein disclosed herein sequence and a second vector comprising a polynucleotide that encodes a TCR. In some aspects, provided herein are a first vector comprising a polynucleotide that encodes the NR4A3 monobody-degrader fusion protein sequence disclosed herein and a second vector comprising a polynucleotide that encodes an alpha chain and a second polynucleotide sequence encoding a beta chain of a TCR. In some aspects, the alpha chain and beta chain are expressed as part of a single polypeptide, such as, for example, an scFv.

[0212] In some aspects, the alpha chain and beta chain are expressed from the vector as two separate polypeptides. In some aspects, provided herein is a first vector comprising a polynucleotide that encodes the NR4A3 monobody-degrader fusion protein disclosed herein sequence and a second vector comprising a polynucleotide that encodes a TCR or functional that targets PRAME.

[0213] In some aspects, the first vector and second vector are transfected into host cells in similar amounts (such as similar molar amounts or similar mass amounts). In some aspects, the first vector and the second vector are the same except for the transgene. In some aspects, the first vector and the second vector are different.

[0214] In some aspects, the vector is an expression vector. The disclosure provides a vector comprising a nucleic acid sequence of the disclosure. In some aspects, the vector is an expression vector. In some aspects, the expression vector is a plasmid, including a mini plasmid. In some aspects, the expression vector comprises a sequence to induce integration or recombination of the nucleic acid sequence of the disclosure into a target genomic sequence of a target cell. In some aspects, the vector comprises a transposable element, that when contacted by a transposase, directs the transfer of the nucleic acid sequence from the vector to a target genomic sequence. In some aspects, the vector comprises one or more “target homologous” sequences at the 5’ and 3’ ends, respectively, of the nucleic acid sequence for insertion. “Target homologous” sequences contain sufficient homology or identify to a target genomic sequence to induce targeted insertion of the nucleic acid sequence of the disclosure by homologous recombination.

[0215] In some aspects, the vector is a delivery vector. In some aspects, the delivery vector is an expression vector. In some aspects of the disclosure, the delivery vector is a viral vector. In some aspects, the vector disclosed herein comprises a sequence isolated or derived from a lentivirus. In some aspects, the delivery vector disclosed herein is a non-viral vector. In some aspects of the disclosure, a delivery vector of the disclosure is capable of maintaining the viability of one or more of nucleic acid, amino acid, folded or complexed proteins, virus(es), or cells and transporting same into an interior space or through a membrane of an intended subject.

[0216] In some aspects, the vector is a viral vector. In some aspects, the vector comprises a retroviral vector, a lentiviral vector, an adeno-associated virus (AAV), an adenovirus, an AAV hybrid virus, a baculovirus, or any combination thereof. In some aspects, the viral vector is a replication-defective virus. In some aspects, the vector comprises at least one sequence isolated or derived from a virus. In some aspects, the vector comprises at least one sequence isolated or derived from a gamma-retrovirus, lentivirus, adenovirus, and adeno-associated virus (AAV). In some aspects, the viral vector is a gammaretroviral vector. In some aspects, the viral vector is a lentiviral vector. In some aspects, the viral vector is an adenoviral vector. In some aspects, the viral vector is an AAV. In some aspects, the AAV comprises at least one sequence isolated or derived from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9. In some aspects, the viral vector is a synthetic, recombinant, or chimeric viral vector, in each case, optionally, a non-naturally occurring viral vector.

[0217] In some aspects, the vector is a non-viral vector. Non-limiting examples of non-viral vectors of the disclosure include, naturally occurring and non-naturally occurring, plasmids (e.g., naked DNA in any primary, secondary, or tertiary shape or form), organic particles, inorganicparticles (e.g., gold particles), nanoparticles, lipid-based vectors, micelles, endosomes, exosomes, liposomes, polymer based vectors, polymersomes, peptide based vectors, and cell-penetrating peptides.IV. Cells

[0218] The present disclosure provides a cell comprising an NR4A3 monobody, a degrader, a fusion protein, a composition, a polynucleotide, or a vector disclosed herein. In some aspects, the cell comprises in vivo cells. It is to be understood that disclosures referring to a “cell” are equally applicable to a population of those cells, i.e., to a plurality of those cells.

[0219] In some aspects, the cell comprises in vitro cells or ex vivo cells.

[0220] In some aspects, the cell expresses an exogenous receptor. In some aspects, the cell is modified or has been modified to express an exogenous receptor. In some aspects, the exogenous receptor comprises a synthetic, recombinant, or chimeric, and in each way, a non-naturally occurring antigen receptor. In some aspects, the exogenous receptor comprises a chimeric antigen receptor (CAR). In some aspects, the exogenous receptor comprises an engineered T cell receptor (TCR), optionally, the engineered TCR is a non-naturally occurring TCR.

[0221] In some aspects, the cell is modified in vitro. In some aspects, the cell is modified ex vivo. In some aspects, the cell is modified in vivo.

[0222] In some aspects, the cell is a eukaryotic cell. In some aspects, the cell is a mammalian cell. In some aspects, the cell is isolated or derived from a non-human primate. In some aspects, the cell is isolated or derived from a human. In some aspects, the cell is an immune cell or a precursor thereof. In some aspects, the cell is a component of the innate immune system. In some aspects, the cell is a component of the adaptive immune system. In some aspects, the cell is a hematopoietic stem cell (HSC). In some aspects, the cell is an induced pluripotent stem cell (IPSC). In some aspects, the cell is a T cell, a B-cell, an NK cell, a macrophage or a hybrid of any one or more of the preceding cells. In some aspects, the T cell is an alpha beta T cell (cc|3 T cell) or a gamma delta T cell (y8 T cell). In some aspects, the T cell is a naive T cell, a memory precursor T cell, an effector T cell, a regulatory T cell, a helper T cell, or a differentially or terminally differentiated T cell. In some aspects, the T cell is a naive T cell (Tn) that expresses CD62L, CCR7, and CD45RA. In some aspects, the T cell is a T stem cell memory cell (Tscm) that expresses CD62L, CCR7, CD45RA and CD45RO. In some aspects, the T cell is a T central memory cell (Tcm) that expresses CD62L, CCR7, and CD45RO. In some aspects, the T cell is a T effectormemory cell (Tern) that expresses CD45RO. In some aspects, the T cell is a T effector cell (Teff) that expresses CD45RA.

[0223] In some aspects, the cells expressing the NR4A3 monobody, the degrader, the fusion protein, or the composition thereof further comprises a moiety that binds to an antigen (“binding moiety”), e.g., a tumor associated antigen (TAA) (TAA binding moiety). In some aspects, the binding moiety that specifically binds to an antigen comprises a chimeric antigen receptor (CAR), a T cell receptor (TCR), a TCR mimetic, or any combination thereof.

[0224] In some aspects, the cells useful for the disclosure can be modified to express a TAA binding moiety prior to the expression of the NR4A3 monobody, the degrader, the fusion protein, or the composition thereof. In some aspects, the cells useful for the disclosure can be modified to express the NR4A3 monobody, the degrader, the fusion protein, or the composition thereof, prior to the expression of a TAA binding moiety.

[0225] In some aspects, the cells of the disclosure express (i) the NR4A3 monobody, the degrader, the fusion protein, or the composition thereof, and (ii) a CAR targeting PRAME, CD 19, TRAC, TCRP, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD70, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, ROR1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Poly sialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT- 2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.

[0226] In some aspects, the cells of the disclosure express (i) the NR4A3 monobody, the degrader, the fusion protein, or the composition thereof, and (ii) a TCR or TCR mimetic targetingPRAME, AFP, CD19, TRAC, TCRp, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, R0R1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CX0RF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.V. Pharmaceutical Compositions

[0227] The disclosure provides a pharmaceutical composition comprising (a) a population of cells that express an NR4A3 monobody, a degrader, a fusion protein, a composition, a polynucleotide, or a vector disclosed herein; and (b) a pharmaceutically acceptable carrier. In some aspects, a pharmaceutical composition of the disclosure is formulated with a pharmaceutically acceptable carrier and includes an NR4A3 monobody, a degrader, a fusion protein, a composition, a polynucleotide, or a vector disclosed herein that can be directly administered to a subject. In some aspects, the pharmaceutically acceptable carrier is a sterile solution, within a tolerate range of physiological pH, optionally, comprising one or more of a preservative, a viscosity agent, and a buffering agent. Alternatively, or in addition, the pharmaceutically acceptable carrier may comprise a naturally occurring element of a eukaryotic or mammalian cell membrane (including intracellular membrane(s)).

[0228] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and otherorganic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN®, PLURONICS® or polyethylene glycol (PEG).

[0229] A pharmaceutical composition can be formulated for any route of administration to a subject. Specific examples of routes of administration include intramuscularly, subcutaneously, ophthalmic, intravenously, intraperitoneally, intradermally, intraorbitally, intracerebrally, intracranially, intraspinally, intraventricular, intrathecally, intraci stemally, intracapsularly, or intratum orally. Parenteral administration, characterized by either subcutaneous, intramuscular or intravenous injection, is also contemplated herein. Pharmaceutical compositions provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such targeting methods are well known to those of skill in the art.VI. Methods of Use

[0230] Provided herein are methods for conditioning one or more cells prior to a therapy comprising contacting the one or more cells with the NR4A3 monobody, the degrader, the fusion protein, the polynucleotide, the vector, or the composition disclosed herein. In some aspects, the contacting improves one or more functions of the cell, e.g., reduce cell exhaustion. In some aspects, the modified cells are used for a therapy.

[0231] By targeting NR4A3, the pro-exhaustion transcription factor, the monobody, the degrader, the fusion protein, the polynucleotide, the vector, or the composition of the disclosure can be used to reduce exhaustion in immune cells, for example T cells or NK cells. By reducing exhaustion in T cells orNK cells, the monobody, the degrader, the fusion protein, the composition, the polynucleotide, the vector, or the pharmaceutical composition of the disclosure can be used to condition the cells for treating diseases or disorders.

[0232] Accordingly, in some aspects provided herein is a method comprising the use of the monobody, degrader, or fusion proteins of the disclosure to condition or improve (e.g., reduce exhaustion in) immune cells comprising expressing the polypeptides during periods of transfecting or culturing of the immune cells expressing a TCR or CAR.

[0233] In some aspects, provided herein is a method comprising the use of the polynucleotide of the disclosure to condition or improve (e.g., reduce exhaustion in) immune cells comprising expressing the polypeptides encoded by the polynucleotide during periods of transfecting or culturing of the immune cells expressing a TCR or CAR. In some aspects, the nucleotides comprise a regulatory sequence. In some aspects, the regulatory sequence is a promoter, optionally an inducible promoter.

[0234] In some aspects, provided herein is a method comprising the use of the vectors of the disclosure to condition or improve (e.g., reduce exhaustion in) immune cells comprising expressing the polypeptides encoded by the vector during periods of transfecting or culturing of the immune cells expressing a TCR or CAR. In some aspects, the vector is an expression vector. In some aspects, the vector is a delivery vector. In some aspects, the vector is a viral vector. In some aspects, the vector is a non-viral vector.

[0235] In some aspects, provided herein is a method comprising the use of the compositions of the disclosure to condition or improve (e.g., reduce exhaustion in) immune cells comprising expressing the polypeptides encoded by the composition or contained in the composition during periods of transfecting or culturing of the immune cells expressing a TCR or CAR. In some aspects, the composition comprises the polypeptides of the disclosure. In some aspects, the composition comprises the nucleotides of the disclosure. In some aspects, the composition comprises the vectors of the disclosure.

[0236] The disclosure provides use of a monobody or a degrader of the disclosure, a fusion protein of the disclosure, a polynucleotide of the disclosure, a vector of the disclosure, or a composition of the disclosure, for conditioning or improving (e.g., reducing exhaustion in) an immune cell comprising introducing the monobody, degrader, fusion protein, polynucleotide, vector or composition into the cell under conditions sufficient for expression of the monobody, degrader, the fusion protein, the polynucleotide, or the vector. In some aspects, the introduction is performed in vitro, ex vivo or in vivo.

[0237] In some aspects, the disclosure comprises one or more cells that are modified or engineered with the NR4A3 monobody, the degrader, the fusion protein, the polynucleotide, or the vector of the present disclosure. In some aspects, the modified or engineered cell is capable oftreating a disease or disorder. In some aspects, the disease or disorder comprises a proliferative disease. In some aspects, the disease or disorder comprises cancer. In some aspects, the disease or disorder comprises an autoimmune disease or disorder. In some aspects, the disease or disorder comprises an inflammatory disease or disorder.

[0238] The disclosure provides a method of preventing exhaustion in a cell, the method comprising introducing a composition of the disclosure, a fusion protein of the disclosure, a polynucleotide of the disclosure, a vector of the disclosure or a composition of the disclosure into a cell under conditions sufficient for expression of the composition, the fusion protein, the polynucleotideor the vector. In some aspects, the introduction is performed in vitro, ex vivo or in vivo. In some aspects, the cell is an immune cell that expresses one or more of the composition, fusion protein, and nucleic acid. In some aspects, the cell is capable of being antigen-stimulated. In some aspects, the cell is capable of treating a disease or disorder. In some aspects, the disease or disorder comprises a proliferative disease. In some aspects, the disease or disorder comprises cancer. In some aspects, the disease or disorder comprises an autoimmune disease or disorder. In some aspects, the disease or disorder comprises an inflammatory disease or disorder.VII. Kits

[0239] The present disclosure also provides kits for practicing any of the methods of the present disclosure.

[0240] The present disclosure further provides a kit or package comprising at least one container means having disposed therein at least one of the above-mentioned NR4A3 monobody, degrader, polynucleotide, vector, cells, or combinations thereof, together with instructions for degradation of NR4A3 protein. In some aspects, the kit comprises one or more cells, cultures, or populations of cells expressing a CAR and / or a TCR targeting a cancer antigen.TABLE 3. TABLE OF SEQUENCES

[0241] In the case of a fusion protein comprising a degrader and an NR4A3 monobody, the sequence of the degrader domain is provided in underline, and the sequence of the monobody is provided in bold.SEQ ID NO Description Sequence1-17 See Table 118 Not usedNot usedthe wild- type tenth VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGG module of the human NSPVOEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSP fibronectin type III ASSKPISINYRTdomain (10Fn3 )- See Table 2Exemplary consensus GX1X2X3X4VX5sequence for FG loopExemplary consensus SWX1X2RVX3sequence for FG loopExemplary consensus PGX6X7X8sequence for DE loopExemplary consensus FXgGFXioHRLHXnsequence for BC loopExemplary consensus XgNGYKWYHsequence for BC loopWild type SPOP MSRVPSPPPPAEMSSGPVAESWCYTQIKVVKFSYMWTINNF SFCREEMGEVIKSSTFSSGANDKLKWCLRVNPKGLDEESKD(Uniprot Accession No .YLSLYLLLVSCPKSEVRAKFKFSILNAKGEETKAMESQRAY043791)RFVQGKDWGFKKFIRRDFLLDEANGLLPDDKLTLFCEVSVV QDSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLC VAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDV EPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKV MCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYH ASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRK RLKQSExemplary degrader VNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAG SPOP ( 167-374 ) QEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPE VFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCE DALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASD VLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLK QSExemplary degrader amino VNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAG acid sequence SPOP ( 167- QEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPE 355) No NLS VFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCE DALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASD VLETSGWKSMVVSHPHLVAEAYRSExemplary degrader amino MVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAIL acid sequence SPOP ( 178 - AARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIY 374 ) TGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVE NAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSM VVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSExemplary degrader amino MVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAIL acid sequence SPOP ( 178 - AARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIY 295+358 -374 ) TGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSSAQCPFLGPPRKRLKQSExemplary degrader amino MVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAIL acid sequence SPOP ( 178 - AARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIY 329+358 -374 ) TGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVE NAAEILILADLHSADQLKTQAVDFINYHASAQCPFLGPPRK RLKQSExemplary degrader amino RRARRPRGRRARRPRGGGGGSSSPRNGTVHLYLTKPLYTSA acid sequence NLS-SOCS2 PSLQHLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQV ( 143 - 198 )Exemplary degrader amino YVAAPRRMLGAPLRQRRVRSLQHLCRLTINKCTGAIWGLPL acid sequence SOCS2box- PTRLKDYLEEYKFQVSOCS1NLSExemplary degrader amino MPS I KLQSSDGE I FEVDVE I AKQSVTI KTMLEDLGMDDEGD acid sequence SKP1 (L) - DDPVPLPNVNAAILKKVIQWCTHHKDDPPPPEDDENKEKRT SKP2 (L) DDIPVWDQEFLKVDQGTLFELILAANYLDIKGLLDVTCKTV ANMIKGKTPEEIRKTFNIKNDGSRENFPGVSWDSLPDELLL GIFSCLCLPELLKVSGVCKRWYRLASDESLWQTExemplary degrader amino RRARRPRGRRARRPRGGGGGSSSMPS I KLQSSDGE I FEVDV acid sequence NLS (CaV) - EIAKQSVTIKTMLEDLGMDDEGDDDPVPLPNVNAAILKKVI SKP1 (L) -SKP2 (L) QWCTHHKDDPPPPEDDENKEKRTDDIPVWDQEFLKVDQGTL FELILAANYLDIKGLLDVTCKTVANMIKGKTPEEIRKTFNI KNDGSRENFPGVSWDSLPDELLLGIFSCLCLPELLKVSGVC KRWYRLASDESLWQTExemplary degrader amino SKTTIFTDGSGSYVKLISSDGHEIIVKRELALTSGTIKAML acid sequence EloB ( 10- SGPGQFAENETNEVNFREIPSHVLIKVAEYFLYKVRYTNSS 17) (G2S2 ) EloC (M3 ) - TEIPEFPIAPEIALELLMAANFLDCGSLQHLCRLTINKCTG SOCS2box ( 161- 198 ) AIWGLPLPTRLKDYLEEYKFQVExemplary degrader amino MDVFLMIRRHKTTIFTDAKESSTVFELKRIVEGILKRPPDE acid sequence QRLYKDDQLLDDGKTLGECGFTSQTARPQAPATVGLAFRAD EloB (WT) (G5S5) EloC (WT) - DTFEALCIEPFSSPPELPDKPQDSGSSANEQAGSGSGSEGS SOCS2box ( 161- 198 ) GSYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENE TNEVNFRE I PSHVLSKVCMYFTYKVRYTNSSTE I PE FP I AP EIALELLMAANFLDCGSGTSAPSLQHLCRLTINKCTGAIWG LPLPTRLKDYLEEYKFQVExemplary degrader amino MATLVELPDSVLLEIFSYLPVRDRIRISRVCHRWKRLVDDR acid sequence FBXL12 WLWRHVDLTLYTMRPKVMWHLLRRYMASRLHSLRMGGYLFS GSQAPQLSPALLRALGQKCPNLKRLCLHVADLSMVPITSLP STLRTLELHSCEISMAWLHKQQDPTVLPLLECIVLDRVPAF RDEHLQGLTRFRALRSLVLGGTYRVTETGLDAGLQELSYLQ RLEVLGCTLSADSTLLAISRHLRDVRKIRLTVRGLSAPGLA VLEGMPALESLCLQGPLVTPEMPSPTEILSSCLTMPKLRVL ELQGLGWEGQEAEKILCKGLPHCMVIVRACPKESMDWWMExemplary degrader amino PRNGTVHLYLTKPLYTSAPSLQHLCRLTINKCTGAIWGLPL acid sequence SOCS2 ( 143 - PTRLKDYLEEYKFQV198 ) also called SOCS2 - SOCSboxExemplary degrader amino MYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENET acid sequence EloC (WT) - NEVNFRE I PSHVLSKVCMYFTYKVRYTNSSTE I PE FP I APE SOCS2box ( 161- 198 ) IALELLMAANFLDCGSGTSAPSLQHLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQVExemplary degrader amino MGEPGFFVTGDRAGGRSWCLRRVGMSAGWLLLEDGCEVTVG acid sequence RNF8 RGFGVTYQLVSKICPLMISRNHCVLKQNPEGQWTIMDNKSL NGVWLNRARLEPLRVYSIHQGDYIQLGVPLENKENAEYEYE VTEEDWETIYPCLSPKNDQMIEKNKELRTKRKFSLDELAGP GAEGPSNLKSKINKVSCESGQPVKSQGKGEVASTPSDNLDP KLTALEPSKTTGAPIYPGFPKVTEVHHEQKASNSSASQRSL QMFKVTMSRILRLKIQMQEKHEAVMNVKKQTQKGNSKKVVQ MEQELQDLQSQLCAEQAQQQARVEQLEKTFQEEEQHLQGLE IAQGEKDLKQQLAQALQEHWALMEELNRSKKDFEAIIQAKN KELEQTKEEKEKMQAQKEEVLSHMNDVLENELQCIICSEYF IEAVTLNCAHSFCSYCINEWMKRKIECPICRKDIKSKTYSL VLDNCINKMVNNLSSEVKERRIVLIRERKAKRLFExemplary degrader amino MSTPARRRLMRDFKRLQEDPPVGVSGAPSENNIMQWNAVIF acid sequence UBE2B GPEGTPFEDGTFKLVIEFSEEYPNKPPTVRFLSKMFHPNVY ADGSICLDILQNRWSPTYDVSSILTSIQSLLDEPNPNSPAN SQAAQLYQENKREYEKRVSAIVEQSWNDSExemplary degrader amino VKWESLGPESRGRRKVDPEALQVFKEARSVPRTLLCLCRVA acid sequence ASB1 VRRALGKHRLHLIPSLPLPDPIKKFLLHE Exemplary degrader amino METHISCLFPELLAMIFGYLDVRDKGRAAQVCTAWRDAAYH acid sequence FBXL14 KSVWRGVEAKLHLRRANPSLFPSLQARGIRRVQILSLRRSL SYVIQGMANIESLNLSGCYNLTDNGLGHAFVQEIGSLRALN LSLCKQITDSSLGRIAQYLKGLEVLELGGCSNITNTGLLLI AWGLQRLKSLNLRSCRHLSDVGIGHLAGMTRSAAEGCLGLE QLTLQDCQKLTDLSLKHISRGLTGLRLLNLSFCGGISDAGL LHLSHMGSLRSLNLRSCDNISDTGIMHLAMGSLRLSGLDVS FCDKVGDQSLAYIAQGLDGLKSLSLCSCHISDDGINRMVRQ MHGLRTLNIGQCVRITDKGLELIAEHLSQLTGIDLYGCTRI TKRGLERITQLPCLKVLNLGLWQMTDSEKEARGDFSPLFTV RTRGSSRRExemplary degrader amino MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALA acid sequence PRAME IAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLP LGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLD LRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGL STEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNV LRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKL PTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQ FTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLS ITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPL QALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTT LSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDI HGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGD RTFYDPEPILCPCFMPNExemplary degrader amino MDEGGTPLLPDSLVYQIFLSLGPADVLAAGLVCRQWQAVSR acid sequence FBXW5 DEFLWREQFYRYYQVARDVPRHPAAMSWYEEFQRLYDTVPC VEVQTLREHTDQVLHLSFSHSGYQFASCSKDCTVKIWSNDL TISLLHSADMRPYNWSYTQFSQFNKDDSLLLASGVFLGPHN SSSGEIAVISLDSFALLSRVRNKPYDVFGCWLTETSLISGN LHRIGDITSCSVLWLNNAFQDVESENVNVVKRLFKIQNLNA STVRTVMVADCSRFDSPDLLLEAGDPATSPCRIFDLGSDNE EVVAGPAPAHAKEGLRHFLDRVLEGRAQPQLSERMLETKVA ELLAQGHTKPPERSATGAKSKYLIFTTGCLTYSPHQIGIKQ ILPHQMTTAGPVLGEGRGSDAFFDALDHVIDIHGHIIGMGLSPDNRYLYVNSRAWPNGAVVADPMQPPPIAEEIDLLVFDLKTMREVRRALRAHRAYTPNDECFFIFLDVSRDFVASGAEDRH GYIWDRHYNICLARLRHEDVVNSVVFSPQEQELLLTASDDA TIKAWRSPRTMRVLQAPRPRPRTFFSWLASQRRExemplary degrader amino MGEKAVPLLRRRRVKRSCPSCGSELGVEEKRGKGNPISIQL acid sequence FBX024 FPPELVEHIISFLPVRDLVALGQTCRYFHEVCDGEGVWRRI CRRLSPRLQDQGSGVRPWKRAAILNYTKGLYFQAFGGRRRC LSKSVAPLLAHGYRRFLPTKDHVFILDYVGTLFFLKNALVS TLGQMQWKRACRYVVLCRGAKDFASDPRCDTVYRKYLYVLA TREPQEVVGTTSSRACDCVEVYLQSSGQRVFKMTFHHSMTF KQIVLVGQETQRALLLLTEEGKIYSLVVNETQLDQPRSYTV QLALRKVSHYLPHLRVACMTSNQSSTLYVTDQGGVYFEVHT PGVYRDLFGTLQAFDPLDQQMPLALSLPAKILFCALGYNHL GLVDE FGRI FMQGNNRYGQLGTGDKMDRGE PTQVCYLQRP I TLWCGLNHSLVLSQSSEFSKELLGCGCGAGGRLPGWPKGSA SFVKLQVKVPLCACALCATRECLYILSSHDIEQHAPYRHLP ASRVVGTPEPSLGARAPQDPGGMAQACEEYLSQIHSCQTLQ DRTEKMKEIVGWMPLMAAQKDFFWEALDMLQRAEGGGGGVG PPAPET IX GS Linker GGGGS2X GS Linker GGGGSGGGGS3X GS Linker GGGGSGGGGSGGGGS4X GS Linker GGGGSGGGGSGGGGSGGGGS- Not usedWild type SOCS2 (Uniprot MTLRCLEPSGNGGEGTRSQWGTAGSAEEPSPQAARLAKALR Accession No . 014508 ) ELGQTGWYWGSMTVNEAKEKLKEAPEGTFLIRDSSHSDYLL TISVKTSAGPTNLRIEYQDGKFRLDSIICVKSKLKQFDSVV HLIDYYVQMCKDKRTGPEAPRNGTVHLYLTKPLYTSAPSLQ HLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQVExemplary degrader fusion VNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAG with monobody at C- QEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPE terminal VFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCE SPOP ( 167-374 ) -MnB A DALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASD VLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLK QSSSGPVSSVPTKLEWAATPTSLLISWDAGRMWPVTYYRI TYGETGGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAF AGFFHRLHYP I S INYRTGAPExemplary degrader fusion MVSSVPTKLEWAATPTSLLISWDAGRMWPVTYYRITYGET with monobody at N- GGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAFAGFFH terminal RLHYP I S INYRTGS VN I SGQNTMNMVKVPE CRLADE LGGLW : MnB A- SPOP ( 167-374 ) ENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEE (with C-terminal FLAG) SKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAA ADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQL KTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLAS AQCPFLGPPRKRLKQS SGGGSD YKDHDGD YKDHD ID YKDDD DKGGExemplary degrader fusion MD YKDHDGD YKDHD ID YKDDDDKGGGGSVN I S GQNTMNMVK with monobody at C- VPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAAR terminal SPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAA: SPOP ( 167-374 ) -MnB A EILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVS (with N-terminal FLAG) HPHLVAEAYRSLASAQCPFLGPPRKRLKQSSSVSSVPTKLE WAATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVQEFT VPGTKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISINY RTExemplary degrader fusion VNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAG with monobody at C- QEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPE terminal VFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCE SPOP ( 167-374 ) -MnB A DALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASD VLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLK QSS S VS S VPTKLE WAATPTSLL I SWDAGRMWPVTYYRITY GETGGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAFAG FFHRLHYPISINYRTExemplary degrader fusion VSSVPTKLEWAATPTSLLISWDAGRMWPVTYYRITYGETG with monobody at N- GNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAFAGFFHR terminal LHYPISINYRTSSVNISGQNTMNMVKVPECRLADELGGLWE : MnB A- SPOP ( 167-374 ) NSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEES KKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAA DKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLK TQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASA QCPFLGPPRKRLKQSExemplary degrader fusion PRNGTVHLYLTKPLYTSAPSLQHLCRLTINKCTGAIWGLPL with monobody at C- PTRLKDYLEEYKFQVSGGGGGSGGGGSSSVSSVPTKLEWA terminal : SOCS2 ( 143 - ATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVQEFTVPG 198 ) -MnB A TKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRT Exemplary degrader fusion MATLVELPDSVLLEIFSYLPVRDRIRISRVCHRWKRLVDDR with monobody at C- WLWRHVDLTLYTMRPKVMWHLLRRYMASRLHSLRMGGYLFS terminal : FBXL12 -MnB A GSQAPQLSPALLRALGQKCPNLKRLCLHVADLSMVPITSLP STLRTLELHSCEISMAWLHKQQDPTVLPLLECIVLDRVPAF RDEHLQGLTRFRALRSLVLGGTYRVTETGLDAGLQELSYLQ RLEVLGCTLSADSTLLAISRHLRDVRKIRLTVRGLSAPGLA VLEGMPALESLCLQGPLVTPEMPSPTEILSSCLTMPKLRVL ELQGLGWEGQEAEKILCKGLPHCMVIVRACPKESMDWWMSG GGGGSGGGGS S S VS S VPTKLE WAATPTSLL I SWDAGRMWP VTYYRITYGETGGNSPVQEFTVPGTKSTATISGLKPGVDYT I TVYAF AGF FHRLHYP I S INYRTExemplary degrader fusion RRARRPRGRRARRPRGGGGGSSSMPS IKLQSSDGE I FEVDV with monobody at C- EIAKQSVTIKTMLEDLGMDDEGDDDPVPLPNVNAAILKKVI terminal : NLS (CaV) - QWCTHHKDDPPPPEDDENKEKRTDDIPVWDQEFLKVDQGTL SKP1 (L) -SKP2 (L) -MnB A FELILAANYLDIKGLLDVTCKTVANMIKGKTPEEIRKTFNI KNDGSRENFPGVSWDSLPDELLLGIFSCLCLPELLKVSGVC KRWYRLASDESLWQTSGGGGGSSSVSSVPTKLEWAATPTS LLISWDAGRMWPVTYYRITYGETGGNSPVQEFTVPGTKSTA TISGLKPGVDYTITVYAFAGFFHRLHYPISINYRTExemplary degrader fusion RRARRPRGRRARRPRGGGGGSSSPRNGTVHLYLTKPLYTSA with monobody at C- PSLQHLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQVSGG terminal NLS (CaV) - GGGSGGGGS S S VS S VPTKLE WAATPTSLL I SWDAGRMWPV SOCS2 ( 143 - 198 ) -MnB A TYYRITYGETGGNSPVQEFTVPGTKSTATISGLKPGVDYTI TVYAFAGFFHRLHYP I S INYRTExemplary degrader fusion YVAAPRRMLGAPLRQRRVRSLQHLCRLTINKCTGAIWGLPLwith monobody at C- PTRLKDYLEEYKFQVSGGGGGSGGGGSSSVSSVPTKLEWAterminal SOCS2box- ATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVQEFTVPG SOCS1NLS - MnB A TKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISINYRT Exemplary degrader fusion MPS I KLQSSDGE I FEVDVE I AKQSVTI KTMLEDLGMDDEGD with monobody at C- DDPVPLPNVNAAILKKVIQWCTHHKDDPPPPEDDENKEKRT terminal SKP1 (L) -SKP2 (L) DDIPVWDQEFLKVDQGTLFELILAANYLDIKGLLDVTCKTV - MnB A ANMIKGKTPEEIRKTFNIKNDGSRENFPGVSWDSLPDELLL GIFSCLCLPELLKVSGVCKRWYRLASDESLWQTSGGGGGSG GGGS S S VS S VPTKLE WAATPTSLL I SWDAGRMWPVTYYRI TYGETGGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAF AGFFHRLHYP I S INYRTExemplary degrader fusion MGEPGFFVTGDRAGGRSWCLRRVGMSAGWLLLEDGCEVTVG with monobody at C- RGFGVTYQLVSKICPLMISRNHCVLKQNPEGQWTIMDNKSL terminal RNF8 - MnB A NGVWLNRARLEPLRVYSIHQGDYIQLGVPLENKENAEYEYE VTEEDWETIYPCLSPKNDQMIEKNKELRTKRKFSLDELAGP GAEGPSNLKSKINKVSCESGQPVKSQGKGEVASTPSDNLDP KLTALEPSKTTGAPIYPGFPKVTEVHHEQKASNSSASQRSL QMFKVTMSRILRLKIQMQEKHEAVMNVKKQTQKGNSKKVVQ MEQELQDLQSQLCAEQAQQQARVEQLEKTFQEEEQHLQGLE IAQGEKDLKQQLAQALQEHWALMEELNRSKKDFEAIIQAKN KELEQTKEEKEKMQAQKEEVLSHMNDVLENELQCIICSEYF IEAVTLNCAHSFCSYCINEWMKRKIECPICRKDIKSKTYSL VLDNCINKMVNNLSSEVKERRIVLIRERKAKRLFSGGGGGS GGGGS S S VS S VPTKLE WAATPTSLL I SWDAGRMWPVTYYR ITYGETGGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYA FAGFFHRLHYP I S INYRTExemplary degrader fusion MYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENET with monobody at N- NEVNFRE I PSHVLSKVCMYFTYKVRYTNSSTE I PE FP I APE terminal UBE2B-NR4A3 - IALELLMAANFLDCGSGTSAPSLQHLCRLTINKCTGAIWGL monobody PLPTRLKDYLEEYKFQVSGGGGGSGGGGSSSGPVSSVPTKL EWAATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVQEF TVPGTKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISIN YRTExemplary degrader fusion SKTTIFTDGSGSYVKLISSDGHEIIVKRELALTSGTIKAML with monobody at C- SGPGQFAENETNEVNFREIPSHVLIKVAEYFLYKVRYTNSS terminal : EloB ( 10- TEIPEFPIAPEIALELLMAANFLDCGSLQHLCRLTINKCTG 17) (G2S2 ) EloC (M3 ) - AIWGLPLPTRLKDYLEEYKFQVS GGGGGSGGGGSSSGPVSS SOCS2box ( 161- 198 ) -MnB A VPTKLEWAATPTSLLISWDAGRMWPVTYYRITYGETGGNS PVQEFTVPGTKSTATISGLKPGVDYTITVYAFAGFFHRLHY PIS INYRTExemplary degrader fusion MDVFLMIRRHKTTIFTDAKESSTVFELKRIVEGILKRPPDE with monobody at C- QRLYKDDQLLDDGKTLGECGFTSQTARPQAPATVGLAFRAD terminal DTFEALCIEPFSSPPELPDKPQDSGSSANEQAGSGSGSEGS EloB (WT) (G5S5) EloC (WT) - GSYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENE SOCS2box ( 161- 198 ) -MnB A TNEVNFRE I PSHVLSKVCMYFTYKVRYTNSSTE I PE FP I AP EIALELLMAANFLDCGSGTSAPSLQHLCRLTINKCTGAIWG LPLPTRLKDYLEEYKFQVSGGGGGSGGGGSSSGPVSSVPTK LEWAATPTSLLISWDAGRMWPVTYYRITYGETGGNSPVQE FTVPGTKSTATISGLKPGVDYTITVYAFAGFFHRLHYPISI NYRTExemplary degrader fusion MSTPARRRLMRDFKRLQEDPPVGVSGAPSENNIMQWNAVIF with monobody at C- GPEGTPFEDGTFKLVIEFSEEYPNKPPTVRFLSKMFHPNVY terminal ADGSICLDILQNRWSPTYDVSSILTSIQSLLDEPNPNSPANSQAAQLYQENKREYEKRVSAIVEQSWNDSSGGGGGSGGGGSUBE2B-MnB A S S VS S VPTKLE WAATPTSLL I SWDAGRMWPVTYYRITYGE TGGNSPVQEFTVPGTKSTATISGLKPGVDYTITVYAFAGFF HRLHYPISINYRT- NOT USEDNuclear receptor MPCVQAQYSPSPPGSSYAAQTYSSEYTTEIMNPDYTKLTMD subfamily 4 group A LGSTEITATATTSLPSISTFVEGYSSNYELKPSCVYQMQRP member 3 (NR4A3 ) , isoform LIKVEEGRAPSYHHHHHHHHHHHHHHQQQHQQPSIPPASSP alpha , UniProtKB EDEVLPSTSMYFKQSPPSTPTTPAFPPQAGALWDEALPSAP Accession No . Q92570- 1 GCIAPGPLLDPPMKAVPTVAGARFPLFHFKPSPPHPPAPSP AGGHHLGYDPTAAAALSLPLGAAAAAGSQAAALESHPYGLP LAKRAAPLAFPPLGLTPSPTASSLLGESPSLPSPPSRSSSS GEGTCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVC LANKNCPVDKRRRNRCQYCRFQKCLSVGMVKEVVRTDSLKG RRGRLPSKPKSPLQQEPSQPSPPSPPICMMNALVRALTDST PRDLDYSRYCPTDQAAAGTDAEHVQQFYNLLTASIDVSRSW AEKIPGFTDLPKEDQTLLIESAFLELFVLRLSIRSNTAEDK FVFCNGLVLHRLQCLRGFGEWLDSIKDFSLNLQSLNLDIQA LACLSALSMITERHGLKEPKRVEELCNKITSSLKDHQSKGQ ALEPTESKVLGALVELRKICTLGLQRIFYLKLEDLVSPPSI IDKLFLDTLPFNuclear receptor MPCVQAQYSPSPPGSSYAAQTYSSEYTTEIMNPDYTKLTMD subfamily 4 group A LGSTEITATATTSLPSISTFVEGYSSNYELKPSCVYQMQRP member 3 (NR4A3 ) , isoform LIKVEEGRAPSYHHHHHHHHHHHHHHQQQHQQPSIPPASSP beta , UniProtKB Accession EDEVLPSTSMYFKQSPPSTPTTPAFPPQAGALWDEALPSAP No . Q92570- 2 GCIAPGPLLDPPMKAVPTVAGARFPLFHFKPSPPHPPAPSP AGGHHLGYDPTAAAALSLPLGAAAAAGSQAAALESHPYGLP LAKRAAPLAFPPLGLTPSPTASSLLGESPSLPSPPSRSSSS GEGTCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVC LANKNCPVDKRRRNRCQYCRFQKCLSVGMVKEVVRTDSLKG RRGRLPSKPKSPLQQEPSQPSPPSPPICMMNALVRALTDST PRDLDYSRVSFMISCFQMNDQGLYLWLLVIRVDNuclear receptor MHDSIRFGNVDMPCVQAQYSPSPPGSSYAAQTYSSEYTTEI subfamily 4 group A MNPDYTKLTMDLGSTEITATATTSLPSISTFVEGYSSNYEL member 3 (NR4A3 ) , isoform KPSCVYQMQRPLIKVEEGRAPSYHHHHHHHHHHHHHHQQQH 3 , UniProtKB Accession QQPSIPPASSPEDEVLPSTSMYFKQSPPSTPTTPAFPPQAG No . Q92570- 3 ALWDEALPSAPGCIAPGPLLDPPMKAVPTVAGARFPLFHFK PSPPHPPAPSPAGGHHLGYDPTAAAALSLPLGAAAAAGSQA AALESHPYGLPLAKRAAPLAFPPLGLTPSPTASSLLGESPS LPSPPSRSSSSGEGTCAVCGDNAACQHYGVRTCEGCKGFFK RTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLSVGMV KEVVRTDSLKGRRGRLPSKPKSPLQQEPSQPSPPSPPICMM NALVRALTDSTPRDLDYSRYCPTDQAAAGTDAEHVQQFYNL LTASIDVSRSWAEKIPGFTDLPKEDQTLLIESAFLELFVLR LSIRSNTAEDKFVFCNGLVLHRLQCLRGFGEWLDSIKDFSL NLQSLNLDIQALACLSALSMITERHGLKEPKRVEELCNKIT SSLKDHQSKGQALEPTESKVLGALVELRKICTLGLQRIFYL KLEDLVSPPSI IDKLFLDTLPFNuclear receptor MPCIQAQYGTPAPSPGPRDHLASDPLTPEFIKPTMDLASPE subfamily 4 group A AAPAAPTALPSFSTFMDGYTGEFDTFLYQLPGTVQPCSSAS member 1 (NR4A1 ) , isoform SSASSTSSSSATSPASASFKFEDFQVYGCYPGPLSGPVDEA 1 , UniProtKB Accession LSSSGSDYYGSPCSAPSPSTPSFQPPQLSPWDGSFGHFSPS No . P22736 - 1 QTYEGLRAWTEQLPKASGPPQPPAFFSFSPPTGPSPSLAQSPLKLFPSQATHQLGEGESYSMPTAFPGLAPTSPHLEGSGILDTPVTSTKARSGAPGGSEGRCAVCGDNASCQHYGVRTCEGC KGFFKRTVQKNAKYICLANKDCPVDKRRRNRCQFCRFQKCL AVGMVKEVVRTDSLKGRRGRLPSKPKQPPDASPANLLTSLV RAHLDSGPSTAKLDYSKFQELVLPHFGKEDAGDVQQFYDLL SGSLEVIRKWAEKIPGFAELSPADQDLLLESAFLELFILRL AYRSKPGEGKLIFCSGLVLHRLQCARGFGDWIDSILAFSRS LHSLLVDVPAFACLSALVLITDRHGLQEPRRVEELQNRIAS CLKEHVAAVAGEPQPASCLSRLLGKLPELRTLCTQGLQRIF YLKLEDLVPPPPIIDKIFMDTLPFNuclear receptor MWLAKACWSIQSEMPCIQAQYGTPAPSPGPRDHLASDPLTP subfamily 4 group A EFIKPTMDLASPEAAPAAPTALPSFSTFMDGYTGEFDTFLY member 1 (NR4A1 ) , isoform QLPGTVQPCSSASSSASSTSSSSATSPASASFKFEDFQVYG 2 , UniProtKB Accession CYPGPLSGPVDEALSSSGSDYYGSPCSAPSPSTPSFQPPQL No . P22736 -2 SPWDGSFGHFSPSQTYEGLRAWTEQLPKASGPPQPPAFFSF SPPTGPSPSLAQSPLKLFPSQATHQLGEGESYSMPTAFPGL APTSPHLEGSGILDTPVTSTKARSGAPGGSEGRCAVCGDNA SCQHYGVRTCEGCKGFFKRTVQKNAKYICLANKDCPVDKRR RNRCQFCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPKQP PDASPANLLTSLVRAHLDSGPSTAKLDYSKFQELVLPHFGK EDAGDVQQFYDLLSGSLEVIRKWAEKIPGFAELSPADQDLL LESAFLELFILRLAYRSKPGEGKLIFCSGLVLHRLQCARGF GDWIDSILAFSRSLHSLLVDVPAFACLSALVLITDRHGLQE PRRVEELQNRIASCLKEHVAAVAGEPQPASCLSRLLGKLPE LRTLCTQGLQRIFYLKLEDLVPPPPIIDKIFMDTLPFNuclear receptor MPCIQAQYGTPAPSPGPRDHLASDPLTPEFIKPTMDLASPE subfamily 4 group A AAPAAPTALPSFSTFMDGYTGEFDTFLYQLPGTVQPCSSAS member 1 (NR4A1 ) , isoform SSASSTSSSSATSPASASFKFEDFQVYGCYPGPLSGPVDEA 3 , UniProtKB Accession LSSSGSDYYGSPCSAPSPSTPSFQPPQLSPWDGSFGHFSPS No . P22736 -3 QTYEGLRAWTEQLPKASGPPQPPAFFSFSPPTGPSPSLAQS PLKLFPSQATHQLGEGESYSMPTAFPGLAPTSPHLEGSGIL DTPVTSTKARSGAPGGSEGRCAVCGDNASCQHYGVRTCEGC KGFFKVPRSPRWGLLLEMERGWPHPIGTCGLPLGSPPSNuclear receptor MPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEFVK subfamily 4 group A FSMDLTNTEITATTSLPSFSTFMDNYSTGYDVKPPCLYQMP member 2 (NR4A2 ) , isoform LSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYYK 1 , UniProtKB Accession PSSPPTPTTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIE No . P43354 - 1 QRKTPVSRLSLFSFKQSPPGTPVSSCQMRFDGPLHVPMNPE PAGSHHVVDGQTFAVPNPIRKPASMGFPGLQIGHASQLLDT QVPSPPSRGSPSNEGLCAVCGDNAACQHYGVRTCEGCKGFF KRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLAVGM VKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPPVSLISALV RAHVDSNPAMTSLDYSRFQANPDYQMSGDDTQHIQQFYDLL TGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRL AYRSNPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSN LQNMNIDISAFSCIAALAMVTERHGLKEPKRVEELQNKIVN CLKDHVTFNNGGLNRPNYLSKLLGKLPELRTLCTQGLQRIF YLKLEDLVPPPAIIDKLFLDTLPFNuclear receptor MDNYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHS subfamily 4 group A HLPPQSEEMMPHSGSVYYKPSSPPTPTTPGFQVQHSPMWDD member 2 (NR4A2 ) , isoform PGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTP 2 , UniProtKB Accession VSSCQMRFDGPLHVPMNPEPAGSHHVVDGQTFAVPNPIRKP No . P43354 -2 ASMGFPGLQIGHASQLLDTQVPSPPSRGSPSNEGLCAVCGD NAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDK RRRNRCQYCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPK SPQEPSPPSPPVSLISALVRAHVDSNPAMTSLDYSRFQANP DYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRLAYRSNPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTE RHGLKEPKRVEELQNKIVNCLKDHVTFNNGGLNRPNYLSKL LGKLPELRTLCTQGLQRIFYLKLEDLVPPPAIIDKLFLDTL PF99 Exemplary CAR construct MVLQTQVFISLLLWISGAYGQEQLVESGGRLVTPGGSLTLS (R0R1 CAR) CKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSGKTYYAT WVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYAD DGALFNIWGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSP SVSAALGSPAKITCTLSSAHKTDTIDWYQQLQGEAPRYLMQ VQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDEADY YCGADYIGGYVFGGGTQLTVTGESKYGPPCPPCPMFWVLVV VGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQ TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQ LYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY DALHMQALPPR100 Not used101- See Table 1103105 Exemplary consensus VSSVPTKLEVVAATPTSLLISWDAGX1X2X3X4VX5YYRITY sequence for the NR4A3 GETGGNSPVQEFTVPGX6X7X8TATISGLKPGVDYTITVYAF monobody X9GFX10HRLHX11PISINYRT106 Exemplary consensus VSSVPTKLEVVAATPTSLLISWDASWX1X2RVX3YYRITYGE sequence for the NR4A3 TGGNSPVQEFTVPGX6X7X8TATISGLKPGVDYTITVYAX9N monobody GYKWYHPISINYRT107 Exemplary consensus VSSVPTKLEVVAATPTSLLISWDASWX1X2RVX3YYRITYGE sequence for the NR4A3 TGGNSPVQEFTVPGX6X7X8TATISGLKPGVDYTITVYAFRG monobody TTNLKSTPISINYRTEXAMPLESExample 1. Screening Degrader Domains Capable of Down-Regulating NR4A Target Protein.

[0242] To evaluate which degrader domains were capable of degrading NR4A3, a system was generated to bring NR4A3 target protein together with different degrader domains via a designed heterodimer (DHD) protein. Chain A of the designed heterodimer (DHD-A) was fused to HA-tagged NR4A3, and Chain B of the designed heterodimer (DHD-B) was fused to a library of degrader domains. Plasmids were cloned to express these proteins in human and mammalian cells using a lentiviral vector. Primary T cells were dual transduced with one lentiviral vector expressing HA-tagged DHD-A-NR4A3 with a CD 19 transduction marker (tCD19), and another lentiviral vector expressing the DHD-B fused to degrader domains with an EGFR transduction marker. After 3 days of expansion cells were stained by FACS and analyzed for NR4A3 degradation.

[0243] The target degradation score (TDS) was calculated as follows: ([CD19+EGFR- HA MFI] - [CD19+EGFR+ HA MFI]) / ([CD19+EGFR- HA MFI] - [CD19-EGFR- HA MFI]):[ ]::::gating for Target MH[TatgeHDegrader-] ~ [TargeHDegrader-r][TatgeHDegrader-J - [Target-Degrader-][Target High] - [Target-t-Degrader+J[Target High] - [No Target]

[0244] A TDS of 1.0 indicates maximum degradation. The heat map shown in FIG. 2 illustrates the targeted degradation of NR4A3 with 85 different degrader sequences.Example 2. Generation of NR4A3-Specific Monobodies Using Synthetic Phage Library and Affinity Maturation.

[0245] A synthetic monobody phage display library was constructed by adding variation to the BC, DE, and FG loops of a human FN3 scaffold. The phage library was screened against purified biotinylated NR4A3-LBD recombinant protein as follows: NR4A3-LBD antigen was immobilized and presented to phage particles for binding; following binding and washing, an acid elution was performed, and isolated phage particles were used to infect E. coli, which was then prepared for high-throughput DNA sequencing to identify the sequences of potential binder hits. Initial binder panning was followed by rounds of affinity maturation using lower concentration of target NR4A3-LBD protein to identify monobody sequences with stronger binding affinities.Example 3. Measurement of Binding Affinity of Monobodies to Ligand Binding Domain of NR4A.

[0246] An Octet® Platform (Satorius) was used to measure the binding affinities of monobodies identified by the method according to Example 2 to members of the NR4A family ligand binding domain (LBD). Equilibrium dissociation constants (Kd) of the monobodies were measured by capturing purified biotinylated NR4A1-LDB or NR4A3-LBD on streptavidin biosensor tips.

[0247] As shown in FIG. 3, the data demonstrates that the monobody of SEQ ID NO: 21 binds with (a) high affinity to NR4A3 ligand binding domain (Kd ~ 9 nM) and (b) no affinity to NR4A1 ligand binding domain.Example 4. Binding Assay of Monobodies to NR4A family proteins

[0248] The binding Assay of Monobodies to NR4A1, NR4A2 and NR4A3 was conducted in Phosphate Buffer Solution (PBS) and 0.5% Bovine Serum Albumin (BSA). Purified recombinant target protein (biotinylated NR4A1-LBD, NR4A2-LBD, or NR4A3-LBD) was captured onto streptavidin biosensor tips to a level of 1.2nm, and affinity of the binders was measured in solution using a 5-fold dilution series of purified monobody protein over a concentration range of 1 |1M to 0.064 nM. Data plots in FIG. 4 show that monobodies of the present disclosure (SEQ ID NO: 21 and SEQ ID NO: 23) bind selectively to NR4A3 while not binding to NR4A1 orNR4A2 in solution.Example 5. Affinity of Monobody Binding to C-terminal Biotinylated NR4A3 with Freeze / Thaw Cycle.

[0249] Binding assays were performed as described in Examples 3 and 4, using purified NR4A3-LBD that was biotinylated at the C-terminus and captured to a level of ~0.5 nm on streptavidin biosensor tips. A binding titration of purified monobodies of SEQ ID NOS: 23 and 21 was performed using a 4-fold dilution series starting from 1 |1M. The experiment was repeated after the purified protein was thawed following freezing and storage at -80°C.

[0250] Data shown in FIG. 5 demonstrates that the monobodies of the present disclosure maintain binding even after a freeze / thaw cycle.Example 6. Degradation of NR4A3 with Engineered Protein Regulators.

[0251] The monobody of SEQ ID NO: 21 was fused to SPOP, Fbxll2, and SOCS2-SOCSbox degraders to create engineered protein regulators of SEQ ID NOS: 70, 76, and 79, respectively.

[0252] Primary T cells were dual transduced with one lentiviral vector expressing HA-tagged NR4A1, NR4A2, or NR4A3 with an EGFR transduction marker, and another lentiviral vector expressing the engineered protein regulators (monobody binder fused to degrader domain) with a CD 19 transduction marker. After 3 days of expansion cells were stained by FACS and analyzed for NR4A1, NR4A2, and NR4A3 degradation. Targeted degradation score was calculatedas in Example 1, with the following modifications to account for the use of alternate tags: ([CD 19-EGFR+ HA MFI] - [CD19+EGFR+ HA MFI]) / ([CD19-EGFR+ HA MFI] - [CD19-EGFR- HA MFI]).

[0253] The data in FIG. 6 demonstrates the engineered protein regulators of SEQ ID NOS: 70, 76, and 79 are capable of degrading overexpressed NR4A3 target in primary human T cells but do not degrade overexpressed NR4A2 or NR4A1.Example 7. Effect of Engineered Protein Regulators on Tumor Cells.

[0254] To measure effect of engineered protein regulators of the present disclosure on T cell function and the ability to enhance tumor cell killing, an in vitor co-culture assay was performed monitoring cytokine production of the T cells and tumor killing via IncuCyte® (Sartorius) as depicted in FIG. 7A. Primary T cells were thawed and activated for 18-24 hours using TransAct (lOuL / mL) and IL-2 / IL-15 / IL-7. After overnight activation cells were transduced with a tCD19-P2A-Rorl CAR construct (MOI=10). After expansion for 4 days Rorl CAR transduced cells were anti-CD19 bead-purified to select for Rorl CAR+ cells. Immediately after anti-CD19 bead purification cells were again transduced with tEGFR-P2A-ligase-NR4A3monobody constructs (MOI=10). A subset of cells were expanded overnight and then the following day NR4A3 KO cells were generated through CRISPR / Cas9 editing. Once cells have been transduced with all desired vectors they were expanded for 2 days and then anti-EGFR bead purified to select for tEGFR-P2A-ligase-NR4A3 monobody transduced cells. Cells were then expanded for another 5 days and co-cultured with live 2D H1975-mKate2 cells at a 1:1 E:T ratio (Rorl CAR+:H1975; le6 cells / well). T cells were chronically stimulated with live H1975-mKate2 cells in this format for a total of 7 days. Co-cultures were reset on day 2 and day 4 after co-culture setup by harvesting primary T cells and replating onto fresh live H1975-mKate2 cells at a 1:1 E:T ratio (Rorl CAR+:H1975-mKate2; le6 cells / well). After 7 days of chronic stimulation killing assays were then set up with 2D H1975-mKate2 target cells (20,000 cells / well) at 1:2, 1:4, 1:8 or 1:16 E:T ratios (Rorl CAR+:H1975-mKate2). Live cell imaging and kill curves were generated using the IncuCyte for 4-5 days. IncuCyte data was analyzed by calculating the AUC of Red Fluorescence Unit (RFU) Object Count / well (Normalized to t=0). Supernatants from co-cultures were collected 18-24 hours post killing assay setup. Supernatants were frozen at -80 C, then thawed and analyzed for IFN-y and IL-2 secretion by MSD.

[0255] FIG. 7B show the enhanced CAR-T cell function when in the tumor cell killing assay depicted in FIG 7A, exemplary engineered protein regulators are co-expressed with the CARcompared to CAR plus NR4A3 gene knock-out (KO) or CAR only by measuring tumor killing (AUC) and IFN-y production (pg / mL) using two separate donor cells; higher IFN-y production and lower AUC indicate more potent CAR T cell function. The engineered protein regulators of the present dislosure outperformed either CAR plus NR4A3 KO or CAR alone as the increase in IFN-gamma (IFN-y) signifies a greater active immune response in donor cells.

[0256] FIG. 7C demonstrate that in the tumor cell killing assay depicted in FIG 7A, cells expressing the engineered protein regulators of the present disclosure with the binder (monobody) enhance CAR T cell function when fused at either the N-terminus or C-terminus of the SPOP(167-374) ligase (degrader) domain. As shown in FIG. 7C, T-cells expressing the engineered protein regulators killed tumor cells more efficiently than CAR only, activated in the presence of antigen and expressed cytokines interferon-gamma (IFN-D) and interleukin-2 (IL-2) regardless of whether the degrader domain is fused to the monobody via N-terminus or C-terminus.***

[0257] It is to be appreciated that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections can set forth one or more but not all exemplary aspects of the present disclosure as contemplated by the inventor(s), and thus, are not intended to limit the present disclosure and the appended claims in any way.

[0258] The present disclosure has been described above with the aid of functional building blocks illustrating the implementation of specified functions and relationships thereof. The boundaries of these functional building blocks have been arbitrarily defined herein for the convenience of the description. Alternate boundaries can be defined so long as the specified functions and relationships thereof are appropriately performed.

[0259] The foregoing description of the specific aspects will so fully reveal the general nature of the disclosure that others can, by applying knowledge within the skill of the art, readily modify and / or adapt for various applications such specific aspects, without undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed aspects, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

[0260] The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary aspects, but should be defined only in accordance with the following claims and their equivalents.

[0261] The contents of all cited references (including literature references, U.S. or foreign patents or patent applications, and websites) that are cited throughout this application are hereby expressly incorporated by reference as if written herein in their entireties for any purpose, as are the references cited therein. Where any inconsistencies arise, material literally disclosed herein controls.

Claims

1. WHAT IS CLAIMED IS:

1. A monobody or antigen-binding portion thereof specifically binding to nuclear receptor subfamily 4 group A member 3 (NR4A3) (“NR4A3 monobody) comprising an FG loop, a DE loop, and a BC loop, wherein the FG loop comprises the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 1032. TheNR4A3 monobody of claim 1, wherein the BC loop comprises the amino acid sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 101.

3. The NR4A3 monobody of claim 1 or 2, wherein the DE loop comprises the amino acid sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 102.

4. The NR4A3 monobody of any one of claims 1 to 3, wherein the FG loop, DE loop, and BC loop comprise (i) the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 3, respectively, (ii) the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 4, respectively, or (ii) the amino acid sequence as set forth in SEQ ID NO: 103, SEQ ID NO: 102, and SEQ ID NO: 101, respectively.

5. The NR4A3 monobody of any one of claims 1 to 4, which does not bind to NR4A1 or NR4A2.

6. The NR4A3 monobody of any one of claims 1 to 5, wherein the NR4A3 comprises the amino acid sequence as set forth in SEQ ID NO: 91.

7. The NR4A3 monobody of any one of claims 1 to 6, which binds to a ligand binding domain (LBD) oftheNR4A3.

8. The NR4A3 monobody of claim 7, wherein the LBD of the NR4A3 comprises amino acids amino acids 394-626 of SEQ ID NO:

919. The NR4A3 monobody of any one of claims 1 to 8, wherein the NR4A1 comprises the amino acid sequence as set forth in any one of SEQ ID NOs: 96-98.

10. The NR4A3 monobody of any one of claims 1 to 9, wherein the NR4A2 comprises the amino acid sequence as set forth in SEQ ID NO: 94 or SEQ ID NO: 95.

11. The NR4A3 monobody of any one of claims 1 to 10, wherein the NR4A3 monobody has a KD less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 55 nM, less than about 50 nM, less than about 45 nM, less than about 40 nM, less than about 35 nM, less than about 30 nM, less than about 25 nM, less than about 20 nM, less than about 19 nM, less than about 18 nM, less than about 17 nM, less than about 16 nM, less than about 15 nM, less than about 14 nM, less than about 13 nM, less than about 12 nM, less than about 11 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, or less than about 1 nM.

12. The NR4A3 monobody of any one of claims 1 to 11, which further comprises a AB loop, a CD loop, and a EF loop.

13. The NR4A3 monobody of claim 12, wherein the AB loop comprises the amino acid sequence as set forth in SEQ ID NO: 9.

14. The NR4A3 monobody of claim 12 or 13, wherein the CD loop comprises the amino acid sequence as set forth in SEQ ID NO: 12.

15. The NR4A3 monobody of any one of claims 12 to 14, wherein the EF loop comprises the amino acid sequence as set forth in SEQ ID NO: 15.

16. The NR4A3 monobody of any one of claims 1 to 15, further comprising one or more beta strand domains comprising A sheet, B sheet, C sheet, D sheet, E sheet, F sheet, or G sheet.

17. The NR4A3 monobody of claim 16, wherein the A sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 8.

18. TheNR4A3 monobody of claim 16, wherein the B sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 10.

19. The NR4A3 monobody of claim 16, wherein the C sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 11.

20. The NR4A3 monobody of claim 16, wherein the D sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 13.

21. The NR4A3 monobody of claim 16, wherein the E sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 14.

22. The NR4A3 monobody of claim 16, wherein the F sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 16.

23. TheNR4A3 monobody of claim 16, wherein the G sheet comprises an amino acid sequence having one, two, or three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 17.

24. The NR4A3 monobody of any one of claims 1 to 23, further comprising an N terminal sequence comprising an amino acid sequence having one, two, three amino acid substitutions, deletions, and / or insertions to the amino acid sequence corresponding to SEQ ID NO: 7.

25. The NR4A3 monobody of any one of claims 1 to 24, which comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to (i) the amino acid sequence as set forth in SEQ ID NO: 21, (ii) the amino acid sequence as set forth in SEQ ID NO: 22, or (iii) the amino acid sequence as set forth in SEQ ID NO: 23.

26. A monobody or antigen-binding portion thereof that specifically binds to NR4A3 (“NR4A3 monobody”), the NR4A3 monobody comprising the amino acid sequence as set forth in SEQ ID NO: 21.

27. A monobody or antigen-binding portion thereof that specifically binds to NR4A3 (“NR4A3 monobody”), the NR4A3 monobody comprising the amino acid sequence as set forth in SEQ ID NO: 22.

28. A monobody or antigen-binding portion thereof that specifically binds to NR4A3 (“NR4A3 monobody”), the NR4A3 monobody comprising the amino acid sequence as set forth in SEQ ID NO: 23.

29. The NR4A3 monobody of any one of claims 1 to 28, which further comprises a heterologous moiety.

30. The NR4A3 monobody of claim 28, wherein the heterologous moiety comprises a heterologous polypeptide.

31. The NR4A3 monobody of claim 29 or 30, wherein the heterologous moiety comprises a half-life extending moiety.

32. The NR4A3 monobody of claim 31, wherein the half-life extending moiety comprises Fc, XTEN, albumin, PAS sequences, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of human chorionic gonadotropin (hCG) with 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin-binding polypeptides, albumin-binding small molecules, or any combination thereof.

33. A fusion protein comprising the NR4A3 monobody of any one of claims 1 to 32 and a degrader, which is capable of degrading NR4A3.

34. The fusion protein of claim 33, wherein the degrader comprises a functional domain from SPOP, FBXL12, SOCS2, RNF8, 3xUb(K48R), ABTB1, ASB1, ASB6, c-cbl, cbl-b, CHIP, CISH, CRBN, DCAF15, DDB2, EID1, ELOC, FBW1A, FBXL12, FBXL14, FBXL15, FBXO24, FBXO3, FBXO40, FBXO6, FBXW5, FBXW7, FCGR3B, GABARAP, GABARAPL2, GAN, GET4, GID8, GMCL1, HDAC1, ISG15, KBTBD7, KLHDC2, KLHL11, KLHL12, KLHL23, KLHL40, KLHL6, LAPTM5, LD0C1, LNX1, LY6D, LYPD3, MAGEA2B, MAP1LC3A, March8, MTCH1, MYLIP, NDFIP2, NEDD4, NHLRC1, 0TUB1, PCGF3, PIAS3, PIAS4 (gamma), PJA1, PPARgamma, PRAME, PRR20A, RAB40AL, RCHY1, RNF115, RNF123, RNF123 truncated, RNF125, RNF126, RNF130, RNF138, RNF144A, RNF144B, RNF150, RNF166, RNF181, RNF182, RNF183, RNF185, RNF24, RNF4, RNF41, RNF43, RTL8C, SKP1, SKP2, SOCS1, SOCS3, SOCS5, SPSB2, SPSB4, SQSTM1, TEX19, TRAF2, TRAF6, Triml3, TRIM31, TRIM39, TRIM49, TRIM5, UBC9, UBE2A, UBE2B, UBE2D1, UBE2D4, UCHL1, VHL, ZER1, or any combination thereof.

35. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in amino acids 167 to 374 of SPOP , amino acids 143 to 198 of SOCS2, amino acids of FBXL12 , NLS (CaV), SKP1(L), SKP2(L), amino acids of SOCS2box, amino acids of SOCS1NLS, amino acids of RNF8, amino acids of EloC(WT), amino acids 161 to 198 of SOCS2box, amino acids 10-17 ofEloB(WT), amino acids ofEloC(M3), amino acids amino acids of ELoC (WT), amino acids of UBE2B, or any combination thereof.

36. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 167-374 of SEQ ID NO: 40.

37. The fusion protein of claim 33, wherein the degrader comprises amino acids 167-374 of SEQ IDNO: 40.

38. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 143-198 of SEQ ID NO: 69.

39. The fusion protein of claim 33, wherein the degrader comprises amino acids 143-198 of SEQ IDNO: 69.

40. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 52.

41. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 49.

42. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 49.

43. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46.

44. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 46.

45. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 47.

46. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 47.

47. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 48.

48. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 48.

49. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 50.

50. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 50.

51. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 51.

52. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 51.

53. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ IDNO: 55.

54. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 55.

55. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 54.

56. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 54.

57. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 56.

58. The fusion protein of claim 33, wherein the degrader comprises the amino acid sequence set forth in SEQ ID NO: 56.

59. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 57.

60. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ IDNO: 58.

61. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 59.

62. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 60.

63. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ IDNO: 61.

64. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 178-374 of SEQ ID NO: 40.

65. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acids 167-355 of SEQ ID NO: 40.

66. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acid 178-295 and 358-67. The fusion protein of claim 33, wherein the degrader comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to amino acid 178-329 and 358- 374 of SEQ ID NO: 40.

68. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 44.

69. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 45.

70. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46.

71. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 47.

72. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 48.

73. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 49.

74. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 50.

75. A degrader that is capable of degrading a heterologous protein, wherein the degrader comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 51.

76. A fusion protein comprising the degrader of any one of claims 68 to 75, and a binding moiety that specifically binds to the heterologous protein.

77. The fusion protein of claim 76, wherein the binding moiety comprises an antibody or antigen binding portion thereof, a monobody or antigen binding portion thereof, a nanobody or antigen binding portion thereof, or any combination thereof.

78. The fusion protein of any one of claims 76 to 77 or the degrader of any one of claims 68 to 75, wherein the heterologous protein comprises an NR4A3.

79. The fusion protein of any one of claims 76-78, wherein the binding moiety comprises the NR4A3 monobody of any one of claims 1 to 32.

80. The fusion protein of any one of claims 33 to 67 and 76 to 79, wherein the degrader comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 70 to 85.

81. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 70.

82. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 73.

83. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 74.

84. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SPOP protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75.

85. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76.

86. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequencehaving at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77.

87. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78.

88. A fusion protein comprising a monobody that specifically binds to NR4A3 and a SOCS2 protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 79.

89. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 80.

90. A fusion protein comprising a monobody that specifically binds to NR4A3 and a RNF8 protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 81.

91. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, atleast about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 82.

92. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 83.

93. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 84.

94. A fusion protein comprising a monobody that specifically binds to NR4A3 and a protein that is capable of degrading NR4A3, the fusion protein comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 85.

95. The fusion protein of any one of claims 33 to 67 and 76 to 94, wherein the degrader is linked to the NR4A3 monobody directly.

96. The fusion protein of any one of claims 33 to 67 and 76 to 94, wherein the degrader is linked to the NR4A3 monobody via a linker.

97. The fusion protein of any one of claims 33 to 67 and 76 to 96, wherein the degrader is present at the C terminus of the NR4A3 monobody, optionally via a linker.

98. The fusion protein of any one of claims 33 to 67 and 76 to 96, wherein the degrader is present at the N terminus of the NR4A3 monobody, optionally via a linker.

99. The fusion protein of any one of claims 96 to 98, wherein the linker is a non-cleavable linker or a cleavable linker.

100. The fusion protein of any one of claims 96 to 99, wherein the linker comprises a flexible linker or a cleavable linker.

101. The fusion protein of any one of claims 96 to 100, wherein the linker comprises a GS linker.

102. The fusion protein of any one of claims 96 to 100, wherein the linker comprises any one of SEQ ID NO: 62 to SEQ ID NO: 65.

103. The fusion protein of any one of claims 96 to 100, wherein the linker comprises a furin.

104. The fusion protein of any one of claims 33 to 67 and 76 to 103, further comprising a moiety that binds to a tumor associated antigen (TAA) (TAA binding moiety).

105. The fusion protein of claim 104, wherein the TAA binding moiety comprises a chimeric antigen receptor (CAR), a T cell receptor (TCR), a TCR mimetic, or any combination thereof.

106. The fusion protein of claim 104 or 105, wherein the TAA binding moiety is linked to the N-terminus of the monobody, optionally via a BM linker.

107. The fusion protein of claim 104 or 105, wherein the TAA binding moiety is linked to the C-terminus of the monobody, optionally via a BM linker.

108. The fusion protein of claim 104 or 105, wherein the TAA binding moiety is linked to the N-terminus of the degrader, optionally via a BM linker.

109. The fusion protein of claim 104 or 105, wherein the TAA binding moiety is linked to the N-terminus of the degrader, optionally via a BM linker.

110. The fusion protein of any one of claims 105 to 109, wherein the CAR targets PRAME, CD19, TRAC, TCRP, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD70, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, R0R1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPC AM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF -I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD 179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT- 2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.

111. The fusion protein of any one of claims 105 to 109, wherein the TCR or TCR mimetic targets PRAME, AFP, CD 19, TRAC, TCRP, BCMA, CLL-1, CS1, CD38, CD 19, TSHR, CD123, CD22, CD30, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, R0R1, R0R2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL- 13Ra2, mesothelin, IL-1 IRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD 179a, ALK, Poly sialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, legumain, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, surviving, telomerase, PCTA- 1 / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3s, CD4, CD5, CD7, the extracellular portion of the APRIL protein, or any combinations thereof.

112. The fusion protein of any one of claims 106 to 111, wherein the BM linker comprises a cleavable linker.

113. A composition comprising the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112.

114. A polynucleotide encoding the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112.

115. A vector comprising the polynucleotide of claim 114 operably linked to a regulatory element.

116. The vector of claim 115, wherein the vector comprises a retroviral vector, a lentiviral vector, an adeno-associated virus (AAV), an adenovirus, an AAV hybrid virus, a baculovirus, or any combination thereof.

117. A cell comprising the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, or the vector of claim 115 or 116.

118. A cell or cells that are modified or engineered with the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, or the vector of claim 115 or 116.

119. The cell or cells of claim 117 or 118, which comprises a T cell, aB cell, an NK cell, a tumor infiltrating lymphocyte, or any combination thereof.

120. The cell or cells of any one of claims 117 to 119, which comprises in vivo cells, in vitro cells, or ex vivo cells.

121. A pharmaceutical composition comprising the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, or the cell of any claims 117 to 120 and a pharmaceutically acceptable carrier.

122. A method of expressing the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, comprising transfecting a cell with the polynucleotide of any one of claims 114 or the vector of claim 115 or 116 under suitable conditions.

123. A method of reducing or inactivating an NR4A3 activity in a cell comprising contacting the cell with the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, or the pharmaceutical composition of claim 120.

124. A method of increasing a function of in vitro engineered cells comprising contacting cells with the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, thecomposition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, or the pharmaceutical composition of claim 121.

125. A method of preventing exhaustion in a cell, the method comprising introducing the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, into a cell under conditions sufficient for expression of the monobody, degrader, the fusion protein, the composition, the polynucleotideor, or the vector.

126. The use of the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, in conditioning or improving (e.g., reducing exhaustion in) immune cells comprising expressing the polypeptides during periods of transfecting or culturing of the immune cells expressing a TCR or CAR.

127. The use of the the polynucleotide of claim 114 or the vector of claim 115 or 116 in conditioning or improving (e.g., reducing exhaustion in) immune cells comprising expressing the polypeptides encoded by the polynucleotide or the vecetor during periods of transfecting or culturing of the immune cells expressing a TCR or CAR.

128. The use of the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, or the cell of any claims 117 to 120, for treating a disease or disorder comprising providing the composition, fusion protein, nucleic acid, vector or pharmaceutical composition to a subject in need thereof.

129. The use of the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or116, or the cell of any claims 117 to 120, for the manufacture of a medicament for treating a disease or condition in a subject in need of.

130. A method of treating a disease or a condition in a subject in need thereof comprising administering to the subject the NR4A3 monobody of any one of claims 1 to 32, the degrader of any one of claims 68 to 75, or the fusion protein comprising any one of claims 33 to 67 and 76 to 112, the composition of claim 113, the polynucleotide of claim 114, the vector of claim 115 or 116, or the cell of any claims 117 to 120.

131. The method or use of claim 130, wherein the disease or condition comprises a cancer, an autoimmune disease or disorder, or an inflammatory disease or disorder.